{
    "id": "dbpedia_1969_0",
    "rank": 13,
    "data": {
        "url": "https://karger.com/lic/article/10/3/181/202311/Management-of-Hepatocellular-Carcinoma-in-Japan",
        "read_more_link": "",
        "language": "en",
        "title": "Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update",
        "top_image": "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/issue/10/3/2/m_lic_10_n_3_cover.png?Expires=1786226458&Signature=ukgfuWE5Ry69rMNBRquTYJGKE6iOMjls3BpS7sZVYbSNHoERvS8V1MQKj~39GjmXYsBpQxd0QL7zq9vbwWuaO95FkvSkzkCwY5NvJSziSmBqs8JV50yPsXzzBrIZub7-Un0CCuH6DOm84SYHQ~wuZ~nPhmtSP-66AB7QjCdms~8OVnaRCfQd8I-TfiGdE-yRcviV62U3DBoqWwlVW8zA5cCC~gtksLmfdDyJ2QGGBVw6X1DXLecs~zsPFvdIl7L1xyZHtgzbQqfzE7haM5WQyE7yD6NWjSrkY~w5KwrM~DE48H2EApiiPaYG6AbYsO0VJ6CZSEw6Xtum-ebHzioRrA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
        "meta_img": "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/issue/10/3/2/m_lic_10_n_3_cover.png?Expires=1786226458&Signature=ukgfuWE5Ry69rMNBRquTYJGKE6iOMjls3BpS7sZVYbSNHoERvS8V1MQKj~39GjmXYsBpQxd0QL7zq9vbwWuaO95FkvSkzkCwY5NvJSziSmBqs8JV50yPsXzzBrIZub7-Un0CCuH6DOm84SYHQ~wuZ~nPhmtSP-66AB7QjCdms~8OVnaRCfQd8I-TfiGdE-yRcviV62U3DBoqWwlVW8zA5cCC~gtksLmfdDyJ2QGGBVw6X1DXLecs~zsPFvdIl7L1xyZHtgzbQqfzE7haM5WQyE7yD6NWjSrkY~w5KwrM~DE48H2EApiiPaYG6AbYsO0VJ6CZSEw6Xtum-ebHzioRrA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
        "images": [
            "https://karger.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/Karger_RGB_neg.svg",
            "https://karger.silverchair-cdn.com/data/SiteBuilderAssetsOriginals/Live/Images/umbrella/Karger_RGB.svg",
            "https://karger.silverchair-cdn.com/data/SiteBuilderAssets/Live/Images/lic/LIC_logo842478519.png",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/issue/10/3/2/m_lic_10_n_3_cover.png?Expires=1726424869&Signature=NLMtcUUpTGZP8fno4IcknHtBzc88Yy234gvxm~coGYG5TAbHz-sUVLlr9B~ZqCYjIB7mIrPonm5J5wnD5V5ehsnf0fteB5wgJKWw6K-8lABv1iX1cO2mR-IQbaNjPqWK~-C2WcfH~tpm6f2AXtMWrWL1d5QLdy-rMPVFNyzsibo7u~AcpL0EoClf-WFIyOk-BG6ga5VaNpAtH1TOLpV3ab0~F3H4awx-I74Smcpf0tooQ~vaBgrSdvVMgF1A~qv74OS~vNcZovOS6XTCRr~kWc2hPO1Ja2N1KJjk8-57x~gGQhxqa2ggFd1bTRKD5NTZnpIzGCCP48h03FJdbaeCwg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png",
            "https://karger.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png",
            "https://karger.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png",
            "https://karger.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png",
            "https://karger.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png",
            "https://karger.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png",
            "https://karger.silverchair-cdn.com/Themes/Silver/app/img/mini-icon.png",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f01.jpeg?Expires=1726178457&Signature=JANZrlarsibWhzBnPbtYRKgJ0Ah535lRrOuCGABE01g3iW-m7zL0nGD412KNLjlmx2nSzCF9QHHLhK3uzQaFYgA2qqJzNFZR0DpkRFCo1ijRto3X-j3edhK2i-HFBS-E2WqkfHs36BOobfq4~AP5DZjmSlBGws-wwaaRmdttIcU9KlDSmFVrm9IBvCiS7s8ILF2EuGa5dcTsCoZG1NV7-FbaXamYkjNuZRRhwyOXIWrpQ-ZM0UcCDatgBJuIBT66N3KDSwaQqCQFMHBV6nxLHKE7I37OcXMBtOVddhvnMlIWgrV58WseqWZdbOz1GK-Kn6jw04heUizCP1hQMQA6mQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f01.jpeg?Expires=1726178457&Signature=JANZrlarsibWhzBnPbtYRKgJ0Ah535lRrOuCGABE01g3iW-m7zL0nGD412KNLjlmx2nSzCF9QHHLhK3uzQaFYgA2qqJzNFZR0DpkRFCo1ijRto3X-j3edhK2i-HFBS-E2WqkfHs36BOobfq4~AP5DZjmSlBGws-wwaaRmdttIcU9KlDSmFVrm9IBvCiS7s8ILF2EuGa5dcTsCoZG1NV7-FbaXamYkjNuZRRhwyOXIWrpQ-ZM0UcCDatgBJuIBT66N3KDSwaQqCQFMHBV6nxLHKE7I37OcXMBtOVddhvnMlIWgrV58WseqWZdbOz1GK-Kn6jw04heUizCP1hQMQA6mQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t01.png?Expires=1726178457&Signature=j20qUWUUGF0vyrVICjloFwhbiP~HWpjB0l~lQ-NkgsMyKG~UxutaLwTcp7ZDb3vUtphHgNI7-zjwV19KNtbeUXItOwN8lFKAHlaF~3AY2hrKzbQTG9z2ncOA5ybyXw6mozyDQnANzWUO-LZx3dwPM167CcwBlBWrLCeSl7IkgZXfUPMcIrtqIdzxn-7SVpXiLHgo57nmW-NvQOHIVy2TTT6vcnQFPamfDLcd-Ar9QvEamIW40AzCWsMJITdWf9~ITCusDWwCZmSWYob9JSMjWQJxd9bT6kgi1PI~mxEOX54VDvfFkz6B5nRgW0ZRd5xJHxBbI~EvLAUbI6WX7Xu-bQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t01.png?Expires=1726178457&Signature=j20qUWUUGF0vyrVICjloFwhbiP~HWpjB0l~lQ-NkgsMyKG~UxutaLwTcp7ZDb3vUtphHgNI7-zjwV19KNtbeUXItOwN8lFKAHlaF~3AY2hrKzbQTG9z2ncOA5ybyXw6mozyDQnANzWUO-LZx3dwPM167CcwBlBWrLCeSl7IkgZXfUPMcIrtqIdzxn-7SVpXiLHgo57nmW-NvQOHIVy2TTT6vcnQFPamfDLcd-Ar9QvEamIW40AzCWsMJITdWf9~ITCusDWwCZmSWYob9JSMjWQJxd9bT6kgi1PI~mxEOX54VDvfFkz6B5nRgW0ZRd5xJHxBbI~EvLAUbI6WX7Xu-bQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t02.png?Expires=1726178457&Signature=cFER51Twccy~PP~QxCEzQ4aa79HGzJ53j3nDAHBnRbyCP8gP0SFLCMmCpmP2Ovl~Y~dbabU6yn4SgjEJLQ9gcuinBR3wrJoj0ypWn~ivlPTGMDmPuBIbIowe7vIHzm0JINEQ2g6~dNpadIJQZu6BkkLWpUeNAoHlzDLEoYfdCNXTbNjoAhGSZl2~2i3qI~jh2k~HWyf~jALXRwAMAgqp9p~B2YNAkIvEOJrH6S45URggaC02xfOeKmY6bSBcmVeGTK1NY5Qvv9ZKY3PjcaAuy~OfRSiyheR9UrsmcmJUAGU8EtdHmCkwp3hinIc9OrvP4lBaN1NKvWHtV4oGaUuC8Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t02.png?Expires=1726178457&Signature=cFER51Twccy~PP~QxCEzQ4aa79HGzJ53j3nDAHBnRbyCP8gP0SFLCMmCpmP2Ovl~Y~dbabU6yn4SgjEJLQ9gcuinBR3wrJoj0ypWn~ivlPTGMDmPuBIbIowe7vIHzm0JINEQ2g6~dNpadIJQZu6BkkLWpUeNAoHlzDLEoYfdCNXTbNjoAhGSZl2~2i3qI~jh2k~HWyf~jALXRwAMAgqp9p~B2YNAkIvEOJrH6S45URggaC02xfOeKmY6bSBcmVeGTK1NY5Qvv9ZKY3PjcaAuy~OfRSiyheR9UrsmcmJUAGU8EtdHmCkwp3hinIc9OrvP4lBaN1NKvWHtV4oGaUuC8Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t03.png?Expires=1726178457&Signature=cq29EVA2XpFUCb-SBo-BN-82AQHpYLB9nALNdOE2dAsoRWWm7cvWMUPBICXKAZqE6cTjj6MjFNkgc6W2op1i-kxP9ib64FqSe2wBfDsSe9uDLdrGxlO7z~1~NBa57riKOMBOtdS3xcRvhp1VDguaiUfez28WesSU1-YhyXvaxwyC3W7FIQa2dgB4MGqjum4mENSkatvcv04thY-EPVEBGgxGo1Uj0WQ82v8YZgAIDuXkXZsAS9YkwuKC7EQt18gDG3r4QKGaAbpHLqoK2V4JK4iSMGYND1e8hj5EkSr29proSrEgV613~kH23QZ9FvwKRiu~-ugMMoLYGt9FfWkydw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t03.png?Expires=1726178457&Signature=cq29EVA2XpFUCb-SBo-BN-82AQHpYLB9nALNdOE2dAsoRWWm7cvWMUPBICXKAZqE6cTjj6MjFNkgc6W2op1i-kxP9ib64FqSe2wBfDsSe9uDLdrGxlO7z~1~NBa57riKOMBOtdS3xcRvhp1VDguaiUfez28WesSU1-YhyXvaxwyC3W7FIQa2dgB4MGqjum4mENSkatvcv04thY-EPVEBGgxGo1Uj0WQ82v8YZgAIDuXkXZsAS9YkwuKC7EQt18gDG3r4QKGaAbpHLqoK2V4JK4iSMGYND1e8hj5EkSr29proSrEgV613~kH23QZ9FvwKRiu~-ugMMoLYGt9FfWkydw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t04.png?Expires=1726178457&Signature=2M6D7nauAepJvOxDzBOVbufsw-zpohYzr4tR03GyYmkV6QwuUrAnkeFZ6-s7neUwvvMzFHTd0TI78pI-qrLT~RzjAxRLnkCm1UrrZFnl3Sk~jeEMWCy2BU8ymClnMQ7lPiQcdZhjrchUZE4YxMN3QMDMBZH3AAdCisdx-sYHb7nYmCMYnLkjbujSHiGRdLG6EnfmKh6uIYH0ezxusvXQcAMhHI89r0Ppu6yf3tCTMKi5BJrKNC8srSpZbaaDuVoMUnTwWIr2sdgaV6dEnK4jlvFl0MfdMUYKwF8r3mOGxKvWEpIZYk61DTEyDRzY8dn83ydq1aDlSnoipL78dYohUQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t04.png?Expires=1726178457&Signature=2M6D7nauAepJvOxDzBOVbufsw-zpohYzr4tR03GyYmkV6QwuUrAnkeFZ6-s7neUwvvMzFHTd0TI78pI-qrLT~RzjAxRLnkCm1UrrZFnl3Sk~jeEMWCy2BU8ymClnMQ7lPiQcdZhjrchUZE4YxMN3QMDMBZH3AAdCisdx-sYHb7nYmCMYnLkjbujSHiGRdLG6EnfmKh6uIYH0ezxusvXQcAMhHI89r0Ppu6yf3tCTMKi5BJrKNC8srSpZbaaDuVoMUnTwWIr2sdgaV6dEnK4jlvFl0MfdMUYKwF8r3mOGxKvWEpIZYk61DTEyDRzY8dn83ydq1aDlSnoipL78dYohUQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t05.png?Expires=1726178457&Signature=Fn8MGyykfBDZd9GKLcXzLXIY0el-wWz11oCy4Yrtqlg~u7k-qmdcrIrJNks5iO6ZFRmBCPOBUykfqJmOUKZooj0uUPef3erydn5foHqBLmmTHrTzGQTcCKhl5QOYN7xFFbXzl194biFGkCUkwW9plKn~0Um6AiT2-EikXfGffqa0fW2oSbYG1qQbJDSkSW8Zd~FRc1kjscQlhAehi6rDupPYQjVuwk9rS4mp9PFaHsY1pYI1Fxz~akFzJXSsaeOGyOzZdEH~WUOI2Aeur1O9H0KArnnvPcDACWe3Re5wx2xXHrZwMzudPoczp3undSOTZigqb-gulS9KFV4S10TYSg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t05.png?Expires=1726178457&Signature=Fn8MGyykfBDZd9GKLcXzLXIY0el-wWz11oCy4Yrtqlg~u7k-qmdcrIrJNks5iO6ZFRmBCPOBUykfqJmOUKZooj0uUPef3erydn5foHqBLmmTHrTzGQTcCKhl5QOYN7xFFbXzl194biFGkCUkwW9plKn~0Um6AiT2-EikXfGffqa0fW2oSbYG1qQbJDSkSW8Zd~FRc1kjscQlhAehi6rDupPYQjVuwk9rS4mp9PFaHsY1pYI1Fxz~akFzJXSsaeOGyOzZdEH~WUOI2Aeur1O9H0KArnnvPcDACWe3Re5wx2xXHrZwMzudPoczp3undSOTZigqb-gulS9KFV4S10TYSg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t06.png?Expires=1726178457&Signature=B3mr7zgD6NVIxCF8iQQPFCwYMRjoaBj9YPonDvHODbaZLijQzfQ3k9SuKnXRmfcuI27V-5-QaTQ11MXHSzvl5n9GatI81DpXGWWTgRs5Aj1vxhBFrTDZ8kbNmKso7MIfwB2DrRb6lSJPBskAuUmOMWVvMJ8yAX-LWgpkgBGR60xQLDUoxiGt9kcLcbno4KU5d8MbjF1eX4rzGm-uT-J0ZpAVtASrux4wUSkJOfnSWGK7ZRUln4v1DH6eKttNXN11aJYj2ZxM8ZFCTF5pCiG491XmWUc2w3NBsydWtc~LmhZlEqZcFCfydQDDM52V4bkSHngkYY~vNTN~kiUDH3GzxA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t06.png?Expires=1726178457&Signature=B3mr7zgD6NVIxCF8iQQPFCwYMRjoaBj9YPonDvHODbaZLijQzfQ3k9SuKnXRmfcuI27V-5-QaTQ11MXHSzvl5n9GatI81DpXGWWTgRs5Aj1vxhBFrTDZ8kbNmKso7MIfwB2DrRb6lSJPBskAuUmOMWVvMJ8yAX-LWgpkgBGR60xQLDUoxiGt9kcLcbno4KU5d8MbjF1eX4rzGm-uT-J0ZpAVtASrux4wUSkJOfnSWGK7ZRUln4v1DH6eKttNXN11aJYj2ZxM8ZFCTF5pCiG491XmWUc2w3NBsydWtc~LmhZlEqZcFCfydQDDM52V4bkSHngkYY~vNTN~kiUDH3GzxA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f02.jpeg?Expires=1726178457&Signature=Dna8bAdmLMsGvpIdh2idRay9zvMznDzAiFeiIPNjL18GQ3xXRNviOzRrlQDVQARgcqpxDEI5HjMVRu3O3YqIg~bfNPDL-DqC1nSi3VLKQEnpDg3ukcSBrZYJAP2d4E~YWRKMPel0S4iJOVtan-1XmtIpEhRcY03pIoxb61PJo6IFSxEIOrSPPG-40b5bPMRkeEgAqj3RwCLbd~OxpZ9uy1EwO2mcEbYag5IlnbFWs5rxrVDODRgSkwqjE6cM4MDvUgF1KSPJTCa5O11hWfxFR5mSRMq2IYhDcJR7kEnrvdpbHlzQ~ucT4GwFdp2suNMTFtnZKzRhLdTn5lOr9WfsZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f02.jpeg?Expires=1726178457&Signature=Dna8bAdmLMsGvpIdh2idRay9zvMznDzAiFeiIPNjL18GQ3xXRNviOzRrlQDVQARgcqpxDEI5HjMVRu3O3YqIg~bfNPDL-DqC1nSi3VLKQEnpDg3ukcSBrZYJAP2d4E~YWRKMPel0S4iJOVtan-1XmtIpEhRcY03pIoxb61PJo6IFSxEIOrSPPG-40b5bPMRkeEgAqj3RwCLbd~OxpZ9uy1EwO2mcEbYag5IlnbFWs5rxrVDODRgSkwqjE6cM4MDvUgF1KSPJTCa5O11hWfxFR5mSRMq2IYhDcJR7kEnrvdpbHlzQ~ucT4GwFdp2suNMTFtnZKzRhLdTn5lOr9WfsZQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t07.png?Expires=1726178457&Signature=mQrtO5cSoIj3XXSThQ28HcXpfpbDQnuRNZnvsyqBwoaaFmZ4cqyyaiwNzpcAIjWEK4zu~E80ZrJLrodPHqky-2CtHQvxsf29tdVWU~XQyD2Vl73nU9nIa7o-QMbZ5C6cwZjpnBNchmLftdIGDNpdwllOii130yv-mLcwpFWNa5UmpxfCHYDWwIKTWSs~DwLwDaVXqvFR1MS-I4WwG7t5KKpmhmBgOyFbuaoaoafB9Kp-7BFsCIwPFffgCzlIFHuO4wXcYL5RdxbiT7zAc0jkTMgBnRxKLkDE1NKOgFwSlDDjlM8SsNxfo6jayFHjFCvTS8ZmUs3CdI-09XLLAZFX3w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t07.png?Expires=1726178457&Signature=mQrtO5cSoIj3XXSThQ28HcXpfpbDQnuRNZnvsyqBwoaaFmZ4cqyyaiwNzpcAIjWEK4zu~E80ZrJLrodPHqky-2CtHQvxsf29tdVWU~XQyD2Vl73nU9nIa7o-QMbZ5C6cwZjpnBNchmLftdIGDNpdwllOii130yv-mLcwpFWNa5UmpxfCHYDWwIKTWSs~DwLwDaVXqvFR1MS-I4WwG7t5KKpmhmBgOyFbuaoaoafB9Kp-7BFsCIwPFffgCzlIFHuO4wXcYL5RdxbiT7zAc0jkTMgBnRxKLkDE1NKOgFwSlDDjlM8SsNxfo6jayFHjFCvTS8ZmUs3CdI-09XLLAZFX3w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t08.png?Expires=1726178457&Signature=4o0mnfzWEASGbLl6Z-wxDEVxwatuwOLkfwTB8vp-R8cTodPUPtE9AWmk86aRAiQXMi0veBE2IHBk7hG2u0NS5uMqH4Wqo8D-8coFzPLlWsSkTXoRyRIDZik6G6pOgYB~lneC1R~RSE7mLpUxm4BtoxJlEeAz3J0jHJUkv1s2GGF70nJEvvk5YxYbR8A95MDpyAz8~Cct6-GG0iXmTuHk2iOmvGOYjWqNHC3HMAC~oG3hY9fTI1qeSMn67vezyfRRAaL0FFgirQazeRbxUZDaPlLyuG63oPHM8OJBgToE-2Q586hxomUoLg9-XUShsSVm1jYUaXnYspfL1SviqT7RMw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t08.png?Expires=1726178457&Signature=4o0mnfzWEASGbLl6Z-wxDEVxwatuwOLkfwTB8vp-R8cTodPUPtE9AWmk86aRAiQXMi0veBE2IHBk7hG2u0NS5uMqH4Wqo8D-8coFzPLlWsSkTXoRyRIDZik6G6pOgYB~lneC1R~RSE7mLpUxm4BtoxJlEeAz3J0jHJUkv1s2GGF70nJEvvk5YxYbR8A95MDpyAz8~Cct6-GG0iXmTuHk2iOmvGOYjWqNHC3HMAC~oG3hY9fTI1qeSMn67vezyfRRAaL0FFgirQazeRbxUZDaPlLyuG63oPHM8OJBgToE-2Q586hxomUoLg9-XUShsSVm1jYUaXnYspfL1SviqT7RMw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f03.jpeg?Expires=1726178457&Signature=1MJfci0dgFD0aVchbghDX0J-E2QylG8gHh0FudQlpX7J7SlrX6005TsY0gVyowlFZHFlzp7DefiLIk0MVdZ4PYttDmIrhkTo3xEyAr1DpDG4zWPwDR5yqpPMalDqXHHRQZCFHVj9OXAB2~jwviOzmL43z87IP2eerexljPnIHQPzTGne74ERFAPOeFORe3RZtQaGz2xyTDRb80xdKeLimig0CBciXjPLj4qjD80NrdswBhGg5ktFKbr5iamtqa3P-tTahQY5GbPSP0WeLTyTR1aTSTy-jGsz2uh0JCuWMTxtfNjMkm2HStRx~FSmeoEfV4skF0fJ9NVTvkOhymyOFA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f03.jpeg?Expires=1726178457&Signature=1MJfci0dgFD0aVchbghDX0J-E2QylG8gHh0FudQlpX7J7SlrX6005TsY0gVyowlFZHFlzp7DefiLIk0MVdZ4PYttDmIrhkTo3xEyAr1DpDG4zWPwDR5yqpPMalDqXHHRQZCFHVj9OXAB2~jwviOzmL43z87IP2eerexljPnIHQPzTGne74ERFAPOeFORe3RZtQaGz2xyTDRb80xdKeLimig0CBciXjPLj4qjD80NrdswBhGg5ktFKbr5iamtqa3P-tTahQY5GbPSP0WeLTyTR1aTSTy-jGsz2uh0JCuWMTxtfNjMkm2HStRx~FSmeoEfV4skF0fJ9NVTvkOhymyOFA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t09.png?Expires=1726178457&Signature=kTnhBkkdvUtyFVi72ruuH~VwXpGjCPs5xFv-EUQ6MGg7rBfRNVeGnT~Cl8dOs4eFObP41Y2o7Z0oaSPhAjROLAMRyT~nKkrIDx4Esq0kUWFy9WdoZiDoXcWyzDHBQjm5seFJNxs0yF912Yew9KnsOgdNFukVRe4mI2Y7T-a7As89c9S1IPt74MbEYK9C9iTR2XW~f6M8jBqTQMTZ3PKPLZA7H1jUoIcO5paA5VxAd3VrQEpqxWwtj3bd3yFU3oP6ccwAblCetbgFesARZBwPgNSSSOTwIkqz9qUtFtkI6vD~tuNx8Og0-J3X4gzuvDV4xOrlzxlnYsgi3zSbBqUcOw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t09.png?Expires=1726178457&Signature=kTnhBkkdvUtyFVi72ruuH~VwXpGjCPs5xFv-EUQ6MGg7rBfRNVeGnT~Cl8dOs4eFObP41Y2o7Z0oaSPhAjROLAMRyT~nKkrIDx4Esq0kUWFy9WdoZiDoXcWyzDHBQjm5seFJNxs0yF912Yew9KnsOgdNFukVRe4mI2Y7T-a7As89c9S1IPt74MbEYK9C9iTR2XW~f6M8jBqTQMTZ3PKPLZA7H1jUoIcO5paA5VxAd3VrQEpqxWwtj3bd3yFU3oP6ccwAblCetbgFesARZBwPgNSSSOTwIkqz9qUtFtkI6vD~tuNx8Og0-J3X4gzuvDV4xOrlzxlnYsgi3zSbBqUcOw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t10.png?Expires=1726178457&Signature=LZ3WJe4lnHqvTfbmNabQE9ZiWWvy6FjZvxPmb5ft3sDod5KKteNIxhDwp7kYzunjGKADL2KcJPA9GyoYXh1qcVFCZORBjtW26j1iOfVM7dCR-ebJGQdPZo3ox3Pmp0PN-LmHRgNdHJlw6R79S7Ar4lvDzvDa9Y5q3Bc6GzEkIgJB7btsHmj11M1nhu3ZZvvtcZrwM85nojPCX9PZ~QTqhsflOTlh-gd-PTUdKT4eIHmzsOKiFLzAG8RPsZXLiQ540rhdXmPhNHocECiIvaO2w-lS7yowP4uXBeOKS~ij3pNlH3C0frUbkuTsNC6FRYRERa1UVQJjDGF8aBhCP9HjHA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t10.png?Expires=1726178457&Signature=LZ3WJe4lnHqvTfbmNabQE9ZiWWvy6FjZvxPmb5ft3sDod5KKteNIxhDwp7kYzunjGKADL2KcJPA9GyoYXh1qcVFCZORBjtW26j1iOfVM7dCR-ebJGQdPZo3ox3Pmp0PN-LmHRgNdHJlw6R79S7Ar4lvDzvDa9Y5q3Bc6GzEkIgJB7btsHmj11M1nhu3ZZvvtcZrwM85nojPCX9PZ~QTqhsflOTlh-gd-PTUdKT4eIHmzsOKiFLzAG8RPsZXLiQ540rhdXmPhNHocECiIvaO2w-lS7yowP4uXBeOKS~ij3pNlH3C0frUbkuTsNC6FRYRERa1UVQJjDGF8aBhCP9HjHA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f04.jpeg?Expires=1726178457&Signature=xlz9QN7Wx0~YENljU7OkDNzmEdMNBlli1VC94a228j9sdxZ~dvJlXRhGFCeppD6ZcwHW1z4uVgbWLPON6A713jqTp8SFkkKgOJLPTxpmqrDLnPiJhqiWUmVGX3E2qJmQrVRKY~hy3-8WqtFPKh1ZQN9CuYaGq1yDpFQcGyHS6QbSttZ4FwHeWHrKkuVK4dD5lk~5Iz-wg7zFtRoTLJIxITVFwKeNRcPjitneUopQk0G6ibCelFAfPGq~aDed0zzdH~1hH8okHTX-KmFA3un9mnjQ~DtM~STTSfqxOlJUNE4MgX1iNCT3mVAXk0IayCuMXTSZR35DkmSmW5I3Kde71w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f04.jpeg?Expires=1726178457&Signature=xlz9QN7Wx0~YENljU7OkDNzmEdMNBlli1VC94a228j9sdxZ~dvJlXRhGFCeppD6ZcwHW1z4uVgbWLPON6A713jqTp8SFkkKgOJLPTxpmqrDLnPiJhqiWUmVGX3E2qJmQrVRKY~hy3-8WqtFPKh1ZQN9CuYaGq1yDpFQcGyHS6QbSttZ4FwHeWHrKkuVK4dD5lk~5Iz-wg7zFtRoTLJIxITVFwKeNRcPjitneUopQk0G6ibCelFAfPGq~aDed0zzdH~1hH8okHTX-KmFA3un9mnjQ~DtM~STTSfqxOlJUNE4MgX1iNCT3mVAXk0IayCuMXTSZR35DkmSmW5I3Kde71w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f05.jpeg?Expires=1726178457&Signature=NPnyEHHyPjbecAlEPVfQDfJHBzaPri8b~E0I4fR38De099cajgyAEAbQ2ndw6vtizaDyUe~4fEvlZhXHXVQWr-83UpfnkVPOFrvRChpHKwsLI1H7Ztejbp96nZ0WnNgTrziVMYuJVjcso5AEMBeNkbJOmI09L5tkpRm4YBlNEEmYIbbjIFjuy5o60BpUS21RwZ21HmIusp8o4gVVuoGtllL4Erh99f3peSwoYlXvaBj52GXL1z998Vs5U0YMAC4fNmQ4BTLksRHmLYcjYll0eY5Wi2tEepi95K0FPgzHClFNxcG51X1E9Be7Wd4IffM6t4AyzexbpnKz5F9bHI4WkA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f05.jpeg?Expires=1726178457&Signature=NPnyEHHyPjbecAlEPVfQDfJHBzaPri8b~E0I4fR38De099cajgyAEAbQ2ndw6vtizaDyUe~4fEvlZhXHXVQWr-83UpfnkVPOFrvRChpHKwsLI1H7Ztejbp96nZ0WnNgTrziVMYuJVjcso5AEMBeNkbJOmI09L5tkpRm4YBlNEEmYIbbjIFjuy5o60BpUS21RwZ21HmIusp8o4gVVuoGtllL4Erh99f3peSwoYlXvaBj52GXL1z998Vs5U0YMAC4fNmQ4BTLksRHmLYcjYll0eY5Wi2tEepi95K0FPgzHClFNxcG51X1E9Be7Wd4IffM6t4AyzexbpnKz5F9bHI4WkA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f06.jpeg?Expires=1726178457&Signature=AjM1-yByKRhpC2B0JGilXEipcPQNJ81LZsc1-jvBDzMrOKAFzzBEavd4r2E~PtuGcVY4~gnCtQWh0Zwqo-6l7lRwUT9h6m9I~WJ9Q2GSBmYqc8uhFc6g6Fuoo~PEhk9JgiS2K-VT6EYDzV7JwI96Q72YD9zQ~DD0cbZs~dksEZdnMWVeETEnwe9msPh3fo~iK31iQTC9Z-fp2nd6S9qQnN7s23vIucNvmT-JguLjqp2lqnWx3trV3poqR6JAkKbqB8rU81cMU-CFCBEe9r9WroJv1zpxl6wZuoGEiPVc53FClLRrClSrclnHXNbY3ndIzt6RkfhofFGUQhBtcVYSjg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f06.jpeg?Expires=1726178457&Signature=AjM1-yByKRhpC2B0JGilXEipcPQNJ81LZsc1-jvBDzMrOKAFzzBEavd4r2E~PtuGcVY4~gnCtQWh0Zwqo-6l7lRwUT9h6m9I~WJ9Q2GSBmYqc8uhFc6g6Fuoo~PEhk9JgiS2K-VT6EYDzV7JwI96Q72YD9zQ~DD0cbZs~dksEZdnMWVeETEnwe9msPh3fo~iK31iQTC9Z-fp2nd6S9qQnN7s23vIucNvmT-JguLjqp2lqnWx3trV3poqR6JAkKbqB8rU81cMU-CFCBEe9r9WroJv1zpxl6wZuoGEiPVc53FClLRrClSrclnHXNbY3ndIzt6RkfhofFGUQhBtcVYSjg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f07.jpeg?Expires=1726178457&Signature=Z-6qOQpg3zWM5wP8GU4Ae9d3kJqCMiZugKSYGmlOh29CJz5VAOZIwNhkdE2g1voyuWj1flR6XombR4VNkD8kSSqg6y9Sdh3x7IHvJnb~6sbRRCxozBI-uhzH016ZUWGD5uIa-AscY-DxVUaBEWE5pFsStNKPs4Uo7trpMTR1wcVOl~nbbaN0FADmWFL5C0QdXiYay6D7Jc4xESdzXpdtuFi7FoafUPuS4clhQj4rL9cHKikhE0BO0kIqjhXjarymjBlogNT~J~VLmZpKp47Gudw0R0oxEPaSKud1meGEbrDW~0zz5qzyWMBR4p72o2BP7iSBfwslmHeJtZPrfEYWIw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f07.jpeg?Expires=1726178457&Signature=Z-6qOQpg3zWM5wP8GU4Ae9d3kJqCMiZugKSYGmlOh29CJz5VAOZIwNhkdE2g1voyuWj1flR6XombR4VNkD8kSSqg6y9Sdh3x7IHvJnb~6sbRRCxozBI-uhzH016ZUWGD5uIa-AscY-DxVUaBEWE5pFsStNKPs4Uo7trpMTR1wcVOl~nbbaN0FADmWFL5C0QdXiYay6D7Jc4xESdzXpdtuFi7FoafUPuS4clhQj4rL9cHKikhE0BO0kIqjhXjarymjBlogNT~J~VLmZpKp47Gudw0R0oxEPaSKud1meGEbrDW~0zz5qzyWMBR4p72o2BP7iSBfwslmHeJtZPrfEYWIw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f08.jpeg?Expires=1726178457&Signature=bM4IKbmuZjqKAf8chi3Y3OGJdLh5shT3rlBv9B-sDYKI3VBHONBY8QQ4MEjDY0Qc2nHEewWCSPnj0nROeufpzrY0ELr-nIDoIu93xj8MVw3B-WbuQH2Pql0LeK-sX6ODBKFBrfOtGTI4HDZgk~BB3w2YFsYYozOY8TLhpqceA43XUWMIZnZHVAMc7Jmk~EOB8RB1KkNPFD7-l2RKW-nMOD~-g8rMVj1xEChNIGZp7J~5~Mu76GCBohTV6Q7RJxIoVOUVcmYxTQ6VruORYSXXSt46jOFcb098cUf5u-J~AoXVYWInFsv2JCY8xutY4FiKG069nFZFpbILKA3amG0pfg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f08.jpeg?Expires=1726178457&Signature=bM4IKbmuZjqKAf8chi3Y3OGJdLh5shT3rlBv9B-sDYKI3VBHONBY8QQ4MEjDY0Qc2nHEewWCSPnj0nROeufpzrY0ELr-nIDoIu93xj8MVw3B-WbuQH2Pql0LeK-sX6ODBKFBrfOtGTI4HDZgk~BB3w2YFsYYozOY8TLhpqceA43XUWMIZnZHVAMc7Jmk~EOB8RB1KkNPFD7-l2RKW-nMOD~-g8rMVj1xEChNIGZp7J~5~Mu76GCBohTV6Q7RJxIoVOUVcmYxTQ6VruORYSXXSt46jOFcb098cUf5u-J~AoXVYWInFsv2JCY8xutY4FiKG069nFZFpbILKA3amG0pfg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f10.jpeg?Expires=1726178457&Signature=NTV8LwP0g8TNffy1X79JXz~5L3QgdZz63T~DawnoxNUanV0mnlzL7oqB3rOknAuXg-dfTZ7PDP0fZS~vNJRKCRCKCugrr1e8BZpewVmY7ssNM~ce6Bx2w4SxG2Q2fhfarxCoWttnDDduDRN6JVg-l0ZG0ybK2dJcEQaEcjegpZEo9vm-9AyZhV7~y7kUG95W~~i-oWg9QpIBRaV4EBA~jAYI~yjjBNcSa67Ugh--gUKerNQBCu7MCnfW~FF8yBuNmzDOyRYnlhhOzRJ9CwPokInMaso1zXf~8Qoe8FiqWSUAFOSa9zE8RALQ0u9HglaVcDp63P6iAaasjWIbcT4FsQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f10.jpeg?Expires=1726178457&Signature=NTV8LwP0g8TNffy1X79JXz~5L3QgdZz63T~DawnoxNUanV0mnlzL7oqB3rOknAuXg-dfTZ7PDP0fZS~vNJRKCRCKCugrr1e8BZpewVmY7ssNM~ce6Bx2w4SxG2Q2fhfarxCoWttnDDduDRN6JVg-l0ZG0ybK2dJcEQaEcjegpZEo9vm-9AyZhV7~y7kUG95W~~i-oWg9QpIBRaV4EBA~jAYI~yjjBNcSa67Ugh--gUKerNQBCu7MCnfW~FF8yBuNmzDOyRYnlhhOzRJ9CwPokInMaso1zXf~8Qoe8FiqWSUAFOSa9zE8RALQ0u9HglaVcDp63P6iAaasjWIbcT4FsQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t11.png?Expires=1726178457&Signature=gLPlFeI64dZD4OEfKIzEpffCni8uA07ZXVoYUC0MUft7kaBCX8GuNMjon8DOymBZit0iyK8qWto0Nt7Gvhw5kgj~Y6Kxw0bNYNCsuG2iNYOG4WI6Io6ilvmgI0Sl2t9Ttr1bfsvJN24R9Bw1Bp7qONztg~05RoNii6JieJafcc8vm3Wyz1GaADXHqTMng1CwgWjht5BEvEQTUY19h7tGChJivfee9DvUxAQonHDGRyWZZcijz~pp-6so8zjw1TkiYixh~Y~5pJ-LjsAnDz~fp2yrlGFzd79mmAhyioXolVRpEYJE-tA4ysLbdCJFP2Y~d8tnjEaptghq7EvKzNiLYQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t11.png?Expires=1726178457&Signature=gLPlFeI64dZD4OEfKIzEpffCni8uA07ZXVoYUC0MUft7kaBCX8GuNMjon8DOymBZit0iyK8qWto0Nt7Gvhw5kgj~Y6Kxw0bNYNCsuG2iNYOG4WI6Io6ilvmgI0Sl2t9Ttr1bfsvJN24R9Bw1Bp7qONztg~05RoNii6JieJafcc8vm3Wyz1GaADXHqTMng1CwgWjht5BEvEQTUY19h7tGChJivfee9DvUxAQonHDGRyWZZcijz~pp-6so8zjw1TkiYixh~Y~5pJ-LjsAnDz~fp2yrlGFzd79mmAhyioXolVRpEYJE-tA4ysLbdCJFP2Y~d8tnjEaptghq7EvKzNiLYQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t12.png?Expires=1726178457&Signature=vTpVPu7V9De0c5Jy81zFmPspJJEdMjWVs5vxZkFLMMfXBCNKVG51PLgu1eaqtd11Q4zle0cY7igpvp2Ogo4IOYjxzDen4v9is0tQX4xBkkMdwadTWC9CYbf~57-MK90dDikyFrksOPCEx0qxs7uZi3WuPyQXHBhfn7YutKGNg3LAk5beUGX65deBiKSGxncPyOZLXbkQrPrzo7nPGZgkgfrOTFB0ugXY815ivGLeRGj3YiMDoMe2WU-9kCQoPRCsAzjbR1eqRrxCl57GpRcNH0qswiBq~ID4pswwU1FQfuTwM9oXvtkHGNWuXLY5r6NC~4UuTJvaIfTpU~V9dpQ8IQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_t12.png?Expires=1726178457&Signature=vTpVPu7V9De0c5Jy81zFmPspJJEdMjWVs5vxZkFLMMfXBCNKVG51PLgu1eaqtd11Q4zle0cY7igpvp2Ogo4IOYjxzDen4v9is0tQX4xBkkMdwadTWC9CYbf~57-MK90dDikyFrksOPCEx0qxs7uZi3WuPyQXHBhfn7YutKGNg3LAk5beUGX65deBiKSGxncPyOZLXbkQrPrzo7nPGZgkgfrOTFB0ugXY815ivGLeRGj3YiMDoMe2WU-9kCQoPRCsAzjbR1eqRrxCl57GpRcNH0qswiBq~ID4pswwU1FQfuTwM9oXvtkHGNWuXLY5r6NC~4UuTJvaIfTpU~V9dpQ8IQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f09.jpeg?Expires=1726178457&Signature=quMlQDHD9nn4MGvbDSOE93-3FCmkpI1eNM6DLO30oQEHm0fxJpIkWpS~837Sb~MadnH6eoGmzmzb4iQ7pYyx0YPaVey7YfpXKzv7cvcRp9RVo3yfn-5EQkxOiAIBy5gIZD0DMFJ8peTgTYpgYtUmx5ASL0UYay2hBrBL5H3hLJb8opSWsq0IABqA4aPiLrtrKo0lDuqz0x1Mns0zU1o1gIIVz9Zzxh1bYgDuqxfAR6~c3VeVGEKE2sKGoZiu2mlfUijTAJQmrxyjUuvnX-sZSXk941TOdZaDGrHFwpBGCK7eTi0xHzVLYkb194AtVfxeGZmk-nK0DcnF30-pR-Ho1g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f09.jpeg?Expires=1726178457&Signature=quMlQDHD9nn4MGvbDSOE93-3FCmkpI1eNM6DLO30oQEHm0fxJpIkWpS~837Sb~MadnH6eoGmzmzb4iQ7pYyx0YPaVey7YfpXKzv7cvcRp9RVo3yfn-5EQkxOiAIBy5gIZD0DMFJ8peTgTYpgYtUmx5ASL0UYay2hBrBL5H3hLJb8opSWsq0IABqA4aPiLrtrKo0lDuqz0x1Mns0zU1o1gIIVz9Zzxh1bYgDuqxfAR6~c3VeVGEKE2sKGoZiu2mlfUijTAJQmrxyjUuvnX-sZSXk941TOdZaDGrHFwpBGCK7eTi0xHzVLYkb194AtVfxeGZmk-nK0DcnF30-pR-Ho1g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f11.jpeg?Expires=1726178457&Signature=iVREE31py4saAtPh-sOC8wyI6tB5GI6RBTGzkWL~d6dNqDKLgqw0qE5ang~SKfRnsr4iWpUAqANrZ5zCwhJXZRyFhfQzqJHTf1aeStXyPca5w1SLpK-TCCizSVMplWq21JsVNZujIPVuYQV2oEfSpQOgEppkV-uFiGoNE5uF5uHxopmwynSR6S~GpcejEBoQoRSilOw6u2ClpOwI9s7jmcVShyc2AlYnT6CzfIaCJaGmcadQQ8ei4cyQhjP4uhpZjDWUUQXfUGmxBSCrADAVb59SEjt78Ij0ZKyfDg7S-J2XhYQdIoAAxOE2~eNUyvxFSfZZrj65A3UgrGTsqeVvQw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.silverchair-cdn.com/karger/content_public/journal/lic/10/3/10.1159_000514174/2/m_000514174_f11.jpeg?Expires=1726178457&Signature=iVREE31py4saAtPh-sOC8wyI6tB5GI6RBTGzkWL~d6dNqDKLgqw0qE5ang~SKfRnsr4iWpUAqANrZ5zCwhJXZRyFhfQzqJHTf1aeStXyPca5w1SLpK-TCCizSVMplWq21JsVNZujIPVuYQV2oEfSpQOgEppkV-uFiGoNE5uF5uHxopmwynSR6S~GpcejEBoQoRSilOw6u2ClpOwI9s7jmcVShyc2AlYnT6CzfIaCJaGmcadQQ8ei4cyQhjP4uhpZjDWUUQXfUGmxBSCrADAVb59SEjt78Ij0ZKyfDg7S-J2XhYQdIoAAxOE2~eNUyvxFSfZZrj65A3UgrGTsqeVvQw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
            "https://karger.com/Themes/Silver/app/img/license/cc-by-nc.png",
            "https://karger.silverchair-cdn.com/ImageLibrary/umbrella/Karger_RGB_neg.svg?versionId=23030"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Kudo, Masatoshi",
            "Kawamura, Yusuke",
            "Hasegawa, Kiyoshi",
            "Tateishi, Ryosuke",
            "Kariyama, Kazuya",
            "Shiina, Shuichiro",
            "Toyoda, Hidenori",
            "Imai, Yasuharu",
            "Hiraoka, Atsushi",
            "Ikeda, Masafumi"
        ],
        "publish_date": "2021-05-19T00:00:00",
        "summary": "",
        "meta_description": "Abstract. The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice",
        "meta_lang": "en",
        "meta_favicon": "//karger.silverchair-cdn.com/Themes/Client/app/img/favicons/v-638552060564293753/apple-touch-icon.png",
        "meta_site_name": "Karger Publishers",
        "canonical_link": "https://karger.com/lic/article/10/3/181/202311/Management-of-Hepatocellular-Carcinoma-in-Japan",
        "text": "Lenvatinib prior to TACE may provide a better survival benefit for TACE-unsuitable patients, such as those with bilobar multifocal nodules, than TACE without prior lenvatinib [155]. A recent proof-of-concept study showed that pretreatment with lenvatinib followed by TACE in patients who did not meet the up-to-7 criteria and were TACE-naive resulted in favorable outcomes [149]. More specifically, the study compared the treatment outcomes of 37 patients who did not meet the up-to-7 criteria, were classified as Child-Pugh class A, and received pretreatment with lenvatinib without prior TACE for intermediate-stage HCC to those of 139 patients who did not meet the up-to-7 criteria and received TACE during the same period.\n\nInvestigators compared the efficacy of treatment between 30 patients pretreated with lenvatinib (excluding 7 patients who were followed up for <6 months) and 60 propensity score-matched patients treated with TACE alone. TACE caused irreversible impairment in liver function compared with lenvatinib, as determined by the ALBI score. Lenvatinib was associated with significantly longer PFS compared with TACE alone (16.0 vs. 3.0 months; HR: 0.19; 95% CI: 0.10–0.35; p < 0.001). Similar results were obtained for OS: 37.9 months with lenvatinib followed by TACE and 21.3 months with TACE alone (HR: 0.48; 95% CI: 0.16–0.79; p < 0.01), demonstrating a clear advantage of the former over the latter. Approximately 70% of patients pretreated with lenvatinib later received TACE, and 4 achieved CR and were cancer-free and drug-free (including one who became drug-free with lenvatinib alone). Thus, lenvatinib followed by TACE was highly effective in patients who did not meet the up-to-7 criteria and could not be managed with TACE. These results suggest that lenvatinib, which is associated with exceptionally high response rates [155], should be used as first-line treatment for patients with intermediate-stage HCC with a high tumor burden.\n\nFactors contributing to the favorable OS results in the lenvatinib group include the higher response rate and higher preservation of liver function than TACE. The response rate with lenvatinib was 40.6% in the REFLECT trial [139], and a higher response rate was reported in Japanese patients with intermediate-stage HCC (61.3%) [140] and an even higher overall response rate (ORR) in the proof-of-concept study (73.3%) [149]. These high response rates may be attributed to the fact that many TACE-naive patients have ALBI grade 1 liver function and therefore lower rates of AEs, dose reduction, and treatment interruption/discontinuation, thus allowing for the effective administration of lenvatinib [141].\n\nThe high response rate is associated with the following: First, pretreatment with lenvatinib induces tumor regression and necrosis. Second, after pretreatment with lenvatinib, curative selective TACE can be performed in many cases, resulting in preserved liver function. Third, pretreatment with lenvatinib suppresses hypoxia-induced release of VEGF and other cytokines, thereby preventing recurrence or metastasis [127, 166, 167]. Last, normalization of the tumor vasculature with lenvatinib reduces the permeability of blood vessels and the intratumoral interstitial pressure, which improves the delivery of Lipiodol®-containing anticancer drugs throughout the tumor; this increases the embolization effect and results in complete cure (Fig. 4, 5). Therefore, lenvatinib-TACE sequential therapy is theoretically effective for patients with intermediate-stage HCC who do not meet the up-to-7 criteria, and it can be used as a standard treatment for intermediate-stage HCC with a high tumor burden (Fig. 6). In addition, there are almost no disadvantages associated with administering lenvatinib prior to TACE in patients with HCC with high tumor burden. Therefore, this therapeutic strategy represents a dramatic paradigm shift in the treatment of HCC (Fig. 7). The Asia-Pacific Primary Liver Cancer Expert Consensus Statement includes a similar statement [150].\n\nPatients with bilobar multiple nodules or large HCCs can be pretreated with lenvatinib to normalize the tumor vasculature [127], prevent a surge in VEGF levels after TACE, and reduce the residual tumor burden before selective TACE to ensure favorable treatment outcomes and preserve liver functional reserve (Fig. 8). This may also be one of the reasons why, among all clinical trials of TACE plus MTAs, the TACTICS study, in which patients were pretreated with the MTA sorafenib, was the only successful trial [130-135] (Table 7).\n\nTaken together, the current findings indicate that lenvatinib is a rational treatment for TACE-unsuitable patients, such as those who do not meet the up-to-7 criteria. It can be considered as a first-line treatment for conditions such as intermediate-stage HCC with high tumor burden or TACE-resistant HCC, and for patients with ALBI grade 2 (or mALBI grade 2b) liver function. Furthermore, lenvatinib is associated with high response rates in poorly differentiated HCC [168-170], and it is effective against HCCs of the massive nodular type, diffuse/infiltrative type, confluent multinodular type, and simple nodular type with extranodular growth. Thus, lenvatinib-TACE sequential therapy can be a rational and effective treatment not only for patients who do not meet the up-to-7 criteria but also for those with TACE-resistant HCC and those prone to reduced liver functional reserve, such as those classified as ALBI grade 2b (Fig. 7; Table 10).\n\nThere are 3 types of HCCs for which TACE is unsuitable or ineligible (i.e., TACE is not beneficial or is even harmful): (1) lesions that are likely to become TACE refractory after TACE, (2) lesions that predispose patients to deteriorate to Child-Pugh class B liver function, and (3) lesions unlikely to respond to TACE. For patients with these types of intermediate-stage HCC, lenvatinib followed by additional selective TACE will improve the efficacy of TACE and prolong survival [148, 149]. Therefore, lenvatinib and TACE are complementary: pretreatment with lenvatinib enhances the efficacy of TACE, and this does not occur in a competitive manner; both treatments are necessary. A complete understanding of the roles of each treatment modality is necessary for treatment planning in intermediate-stage HCC.\n\nBecause more drugs are being developed, a shift to a new treatment paradigm is highly likely. Systemic drug therapy will be the first choice for patients with intermediate-stage HCC that is not curable with TACE, followed by selective TACE (or even resection or ablation) on an on-demand basis (Fig. 6, 7). Clinical studies are being planned to compare TACE with not only lenvatinib but also with combination immunotherapies, and the results are eagerly awaited (Fig. 10).\n\n1.\n\nThe Japan Society of Hepatology: evidence-based clinical practice guideline for hepatocellular carcinoma\n\n.\n\nTokyo\n\n:\n\nKanehara\n\n;\n\n2005\n\n(in Japanese).\n\n2.\n\nMakuuchi\n\nM\n\n,\n\nKokudo\n\nN\n\n.\n\nClinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan\n\n.\n\nWorld J Gastroenterol\n\n.\n\n2006\n\n;\n\n12\n\n(\n\n5\n\n):\n\n828\n\n–\n\n9\n\n. .\n\n3.\n\nMakuuchi\n\nM\n\n,\n\nKokudo\n\nN\n\n,\n\nArii\n\nS\n\n,\n\nFutagawa\n\nS\n\n,\n\nKaneko\n\nS\n\n,\n\nKawasaki\n\nS\n\n, et al\n\nDevelopment of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan\n\n.\n\nHepatol Res\n\n.\n\n2008\n\n;\n\n38\n\n(\n\n1\n\n):\n\n37\n\n–\n\n51\n\n. .\n\n4.\n\nThe Japan Society of Hepatology: evidence-based clinical practice guideline for hepatocellular carcinoma (2009 updated version)\n\n.\n\nTokyo\n\n:\n\nKanehara\n\n;\n\n2009\n\n. (in Japanese).\n\n5.\n\nMakuuchi\n\nM\n\n,\n\nKokudo\n\nN\n\n.\n\nClinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2009 update\n\n.\n\nHepatol Res\n\n.\n\n2010\n\n;\n\n40\n\n(\n\nSuppl 1\n\n):\n\n2\n\n–\n\n144\n\n.\n\n6.\n\nThe Japan Society of Hepatology: evidence-based clinical practice guideline for hepatocellular carcinoma (2013 updated version)\n\n.\n\nTokyo\n\n:\n\nKanehara\n\n;\n\n2013\n\n. (in Japanese).\n\n7.\n\nKokudo\n\nN\n\n,\n\nHasegawa\n\nK\n\n,\n\nAkahane\n\nM\n\n,\n\nIgaki\n\nH\n\n,\n\nIzumi\n\nN\n\n,\n\nIchida\n\nT\n\n, et al\n\nEvidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)\n\n.\n\nHepatol Res\n\n.\n\n2015\n\n;\n\n45\n\n(\n\n2\n\n):\n\n123\n\n–\n\n7\n\n. .\n\n8.\n\nThe Japan Society of Hepatology: evidence-based clinical practice guideline for hepatocellular carcinoma (2017 updated version)\n\n.\n\nTokyo\n\n:\n\nKanehara\n\n;\n\n2017\n\n(in Japanese).\n\n9.\n\nKokudo\n\nN\n\n,\n\nTakemura\n\nN\n\n,\n\nHasegawa\n\nK\n\n,\n\nTakayama\n\nT\n\n,\n\nKubo\n\nS\n\n,\n\nShimada\n\nM\n\n, et al\n\nClinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update\n\n.\n\nHepatol Res\n\n.\n\n2019\n\n;\n\n49\n\n:\n\n1109\n\n–\n\n13\n\n.\n\n10.\n\nThe Japan Society of Hepatology: clinical practice manual for hepatocellular carcinoma\n\n.\n\nTokyo\n\n:\n\nIgakushoin\n\n;\n\n2007\n\n(in Japanese).\n\n11.\n\nKudo\n\nM\n\n,\n\nOkanoue\n\nT\n\n;\n\nJapan Society of Hepatology\n\n.\n\nManagement of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology\n\n.\n\nOncology\n\n.\n\n2007\n\n;\n\n72\n\n(\n\nSuppl 1\n\n):\n\n2\n\n–\n\n15\n\n.\n\n12.\n\nThe Japan Society of Hepatology: clinical practice manual for hepatocellular carcinoma\n\n. 2nd ed.\n\nTokyo\n\n:\n\nIgakushoin\n\n;\n\n2010\n\n(in Japanese).\n\n13.\n\nKudo\n\nM\n\n,\n\nIzumi\n\nN\n\n,\n\nKokudo\n\nN\n\n,\n\nMatsui\n\nO\n\n,\n\nSakamoto\n\nM\n\n,\n\nNakashima\n\nO\n\n, et al\n\nManagement of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version\n\n.\n\nDig Dis\n\n.\n\n2011\n\n;\n\n29\n\n(\n\n3\n\n):\n\n339\n\n–\n\n64\n\n. .\n\n14.\n\nThe Japan Society of Hepatology: clinical practice manual for hepatocellular carcinoma\n\n. 3rd ed.\n\nTokyo\n\n:\n\nIgakushoin\n\n;\n\n2015\n\n(in Japanese).\n\n15.\n\nKudo\n\nM\n\n,\n\nMatsui\n\nO\n\n,\n\nIzumi\n\nN\n\n,\n\nIijima\n\nH\n\n,\n\nKadoya\n\nM\n\n,\n\nImai\n\nY\n\n, et al\n\nJSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan\n\n.\n\nLiver Cancer\n\n.\n\n2014\n\n;\n\n3\n\n(\n\n3–4\n\n):\n\n458\n\n–\n\n68\n\n. .\n\n16.\n\nKudo\n\nM\n\n,\n\nMatsui\n\nO\n\n,\n\nIzumi\n\nN\n\n,\n\nKadoya\n\nM\n\n,\n\nOkusaka\n\nT\n\n,\n\nMiyayama\n\nS\n\n, et al\n\nTransarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update\n\n.\n\nOncology\n\n.\n\n2014\n\n;\n\n87\n\n(\n\nSuppl 1\n\n):\n\n22\n\n–\n\n31\n\n. .\n\n17.\n\nThe Japan Society of Hepatology: clinical practice manual for hepatocellular carcinoma\n\n. 4th ed.\n\nTokyo\n\n:\n\nIgakushoin\n\n;\n\n2020\n\n(in Japanese).\n\n18.\n\nSakamoto\n\nM\n\n,\n\nHirohashi\n\nS\n\n,\n\nShimosato\n\nY\n\n.\n\nEarly stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma\n\n.\n\nHum Pathol\n\n.\n\n1991\n\n;\n\n22\n\n(\n\n2\n\n):\n\n172\n\n–\n\n8\n\n. .\n\n19.\n\nNakashima\n\nO\n\n,\n\nSugihara\n\nS\n\n,\n\nKage\n\nM\n\n,\n\nKojiro\n\nM\n\n.\n\nPathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins\n\n.\n\nHepatology\n\n.\n\n1995\n\n;\n\n22\n\n(\n\n1\n\n):\n\n101\n\n–\n\n5\n\n. .\n\n20.\n\nThe Liver Cancer Study Group of Japan\n\n.\n\nThe general rules for the clinical and pathological study of primary cancer (6th ed., revised version)\n\n.\n\nTokyo\n\n:\n\nKanehara\n\n;\n\n2019\n\n(in Japanese).\n\n21.\n\nKondo\n\nF\n\n,\n\nKondo\n\nY\n\n,\n\nNagato\n\nY\n\n,\n\nTomizawa\n\nM\n\n,\n\nWada\n\nK\n\n.\n\nInterstitial tumour cell invasion in small hepatocellular carcinoma. Evaluation in microscopic and low magnification views\n\n.\n\nJ Gastroenterol Hepatol\n\n.\n\n1994\n\n;\n\n9\n\n(\n\n6\n\n):\n\n604\n\n–\n\n12\n\n. .\n\n22.\n\nInternational Consensus Group for Hepatocellular Neoplasia\n\n.\n\nPathologic diagnosis of early hepatocellular carcinoma: a report of the International consensus group for hepatocellular neoplasia\n\n.\n\nHepatology\n\n.\n\n2009\n\n;\n\n49\n\n(\n\n2\n\n):\n\n658\n\n–\n\n64\n\n. .\n\n23.\n\nKutami\n\nR\n\n,\n\nNakashima\n\nY\n\n,\n\nNakashima\n\nO\n\n,\n\nShiota\n\nK\n\n,\n\nKojiro\n\nM\n\n.\n\nPathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans\n\n.\n\nJ Hepatol\n\n.\n\n2000\n\n;\n\n33\n\n(\n\n2\n\n):\n\n282\n\n–\n\n9\n\n. .\n\n24.\n\nKitao\n\nA\n\n,\n\nZen\n\nY\n\n,\n\nMatsui\n\nO\n\n,\n\nGabata\n\nT\n\n,\n\nKobayashi\n\nS\n\n,\n\nKoda\n\nW\n\n, et al\n\nHepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging: correlation with molecular transporters and histopathologic features\n\n.\n\nRadiology\n\n.\n\n2010\n\n;\n\n256\n\n(\n\n3\n\n):\n\n817\n\n–\n\n26\n\n. .\n\n25.\n\nNakashima\n\nY\n\n,\n\nNakashima\n\nO\n\n,\n\nTanaka\n\nM\n\n,\n\nOkuda\n\nK\n\n,\n\nNakashima\n\nM\n\n,\n\nKojiro\n\nM\n\n.\n\nPortal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type\n\n.\n\nHepatol Res\n\n.\n\n2003\n\n;\n\n26\n\n(\n\n2\n\n):\n\n142\n\n–\n\n7\n\n. .\n\n26.\n\nKudo\n\nM\n\n.\n\nMultistep human hepatocarcinogenesis: correlation of imaging with pathology\n\n.\n\nJ Gastroenterol\n\n.\n\n2009\n\n;\n\n44\n\n(\n\nSuppl 19\n\n):\n\n112\n\n–\n\n8\n\n. .\n\n27.\n\nYamaguchi\n\nR\n\n,\n\nNakashima\n\nO\n\n,\n\nYano\n\nH\n\n,\n\nKutami\n\nR\n\n,\n\nKusaba\n\nA\n\n,\n\nKojiro\n\nM\n\n.\n\nHepatocellular carcinoma with sarcomatous change\n\n.\n\nOncol Rep\n\n.\n\n1997\n\n;\n\n4\n\n(\n\n3\n\n):\n\n525\n\n–\n\n9\n\n. .\n\n28.\n\nKudo\n\nM\n\n.\n\nAtypical large well-differentiated hepatocellular carcinoma with benign nature: a new clinical entity\n\n.\n\nIntervirology\n\n.\n\n2004\n\n;\n\n47\n\n(\n\n3–5\n\n):\n\n227\n\n–\n\n37\n\n. .\n\n29.\n\nNault\n\nJC\n\n,\n\nParadis\n\nV\n\n,\n\nCherqui\n\nD\n\n,\n\nVilgrain\n\nV\n\n,\n\nZucman-Rossi\n\nJ\n\n.\n\nMolecular classification of hepatocellular adenoma in clinical practice\n\n.\n\nJ Hepatol\n\n.\n\n2017\n\n;\n\n67\n\n(\n\n5\n\n):\n\n1074\n\n–\n\n83\n\n. .\n\n30.\n\nTaketa\n\nK\n\n.\n\nAlpha-fetoprotein: reevaluation in hepatology\n\n.\n\nHepatology\n\n.\n\n1990\n\n;\n\n12\n\n(\n\n6\n\n):\n\n1420\n\n–\n\n32\n\n. .\n\n31.\n\nAoyagi\n\nY\n\n,\n\nSaitoh\n\nA\n\n,\n\nSuzuki\n\nY\n\n,\n\nIgarashi\n\nK\n\n,\n\nOguro\n\nM\n\n,\n\nYokota\n\nT\n\n, et al\n\nFucosylation index of alpha-fetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis\n\n.\n\nHepatology\n\n.\n\n1993\n\n;\n\n17\n\n(\n\n1\n\n):\n\n50\n\n–\n\n2\n\n. .\n\n32.\n\nLiebman\n\nHA\n\n,\n\nFurie\n\nBC\n\n,\n\nTong\n\nMJ\n\n,\n\nBlanchard\n\nRA\n\n,\n\nLo\n\nKJ\n\n,\n\nLee\n\nSD\n\n, et al\n\nDes-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma\n\n.\n\nN Engl J Med\n\n.\n\n1984\n\n;\n\n310\n\n(\n\n22\n\n):\n\n1427\n\n–\n\n31\n\n. .\n\n33.\n\nFujiyama\n\nS\n\n,\n\nMorishita\n\nT\n\n,\n\nHashiguchi\n\nO\n\n,\n\nSato\n\nT\n\n.\n\nPlasma abnormal prothrombin (des-gamma-carboxy prothrombin) as a marker of hepatocellular carcinoma\n\n.\n\nCancer\n\n.\n\n1988\n\n;\n\n61\n\n(\n\n8\n\n):\n\n1621\n\n–\n\n8\n\n. .\n\n34.\n\nTanaka\n\nS\n\n,\n\nKitamra\n\nT\n\n,\n\nFujita\n\nM\n\n,\n\nKasugai\n\nH\n\n,\n\nInoue\n\nA\n\n,\n\nIshiguro\n\nS\n\n.\n\nSmall hepatocellular carcinoma: differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging\n\n.\n\nRadiology\n\n.\n\n1992\n\n;\n\n182\n\n(\n\n1\n\n):\n\n161\n\n–\n\n5\n\n. .\n\n35.\n\nSasaki\n\nS\n\n,\n\nIijima\n\nH\n\n,\n\nMoriyasu\n\nF\n\n,\n\nWaki\n\nH\n\n.\n\nDefinition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles\n\n.\n\nUltrasound Med Biol\n\n.\n\n2009\n\n;\n\n35\n\n:\n\n1819\n\n–\n\n27\n\n.\n\n36.\n\nMoriyasu\n\nF\n\n,\n\nItoh\n\nK\n\n.\n\nEfficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial\n\n.\n\nAJR Am J Roentgenol\n\n.\n\n2009\n\n;\n\n193\n\n(\n\n1\n\n):\n\n86\n\n–\n\n95\n\n. .\n\n37.\n\nClaudon\n\nM\n\n,\n\nDietrich\n\nCF\n\n,\n\nChoi\n\nBI\n\n,\n\nCosgrove\n\nDO\n\n,\n\nKudo\n\nM\n\n,\n\nNolsøe\n\nCP\n\n, et al\n\nGuidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver: update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS\n\n.\n\nUltrasound Med Biol\n\n.\n\n2013\n\n;\n\n39\n\n(\n\n2\n\n):\n\n187\n\n–\n\n210\n\n. .\n\n38.\n\nKudo\n\nM\n\n,\n\nHatanaka\n\nK\n\n,\n\nKumada\n\nT\n\n,\n\nToyoda\n\nH\n\n,\n\nTada\n\nT\n\n.\n\nDouble-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma\n\n.\n\nAm J Gastroenterol\n\n.\n\n2011\n\n;\n\n106\n\n(\n\n2\n\n):\n\n368\n\n–\n\n70\n\n. .\n\n39.\n\nKudo\n\nM\n\n,\n\nUeshima\n\nK\n\n,\n\nOsaki\n\nY\n\n,\n\nHirooka\n\nM\n\n,\n\nImai\n\nY\n\n,\n\nAso\n\nK\n\n, et al\n\nB-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial\n\n.\n\nLiver Cancer\n\n.\n\n2019\n\n;\n\n8\n\n(\n\n4\n\n):\n\n271\n\n–\n\n80\n\n. .\n\n40.\n\nKudo\n\nM\n\n,\n\nHatanaka\n\nK\n\n,\n\nMaekawa\n\nK\n\n.\n\nNewly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma\n\n.\n\nOncology\n\n.\n\n2010\n\n;\n\n78\n\n(\n\nSuppl 1\n\n):\n\n40\n\n–\n\n5\n\n. .\n\n41.\n\nKudo\n\nM\n\n.\n\nDefect Reperfusion Imaging with Sonazoid: a breakthrough in hepatocellular carcinoma\n\n.\n\nLiver Cancer\n\n.\n\n2016\n\n;\n\n5\n\n:\n\n1\n\n–\n\n7\n\n.\n\n42.\n\nDietrich\n\nCF\n\n,\n\nNolsoe\n\nCP\n\n,\n\nBarr\n\nRG\n\n,\n\nBerzigotti\n\nA\n\n,\n\nBums\n\nPN\n\n,\n\nCantisani\n\nV\n\n, et al\n\nGuidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2020: WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS\n\n.\n\nUltrasound Med Biol\n\n.\n\n2020 Oct\n\n;\n\n46\n\n:\n\n2579\n\n–\n\n604\n\n.\n\n43.\n\nDietrich\n\nCF\n\n,\n\nNolsoe\n\nCP\n\n,\n\nBarr\n\nRG\n\n,\n\nBerzigotti\n\nA\n\n,\n\nBums\n\nPN\n\n,\n\nCantisani\n\nV\n\n, et al\n\nGuidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver-update 2020: WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS\n\n.\n\nUltrasound Med Biol\n\n.\n\n2020 Oct\n\n;\n\n46\n\n:\n\n2579\n\n–\n\n604\n\n. Epub ahead of print.\n\n44.\n\nHatanaka\n\nK\n\n,\n\nKudo\n\nM\n\n,\n\nMinami\n\nY\n\n,\n\nUeda\n\nT\n\n,\n\nTatsumi\n\nC\n\n,\n\nKitai\n\nS\n\n, et al\n\nDifferential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid\n\n.\n\nIntervirology\n\n.\n\n2008\n\n;\n\n51\n\n:\n\nS61\n\n–\n\n69\n\n.\n\n45.\n\nHatanaka\n\nK\n\n,\n\nMinami\n\nY\n\n,\n\nKudo\n\nM\n\n,\n\nInoue\n\nT\n\n,\n\nChung\n\nH\n\n,\n\nHaji\n\nS\n\n.\n\nThe gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced US\n\n.\n\nJ Clin Ultrasound\n\n.\n\n2014\n\n;\n\n42\n\n(\n\n1\n\n):\n\n1\n\n–\n\n8\n\n. .\n\n46.\n\nIwamoto\n\nT\n\n,\n\nImai\n\nY\n\n,\n\nKogita\n\nS\n\n,\n\nIgura\n\nT\n\n,\n\nSawai\n\nY\n\n,\n\nFukuda\n\nK\n\n, et al\n\nComparison of contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MRI for the diagnosis of macroscopic type of hepatocellular carcinoma\n\n.\n\nDig Dis\n\n.\n\n2016\n\n;\n\n34\n\n(\n\n6\n\n):\n\n679\n\n–\n\n86\n\n. .\n\n47.\n\nKorenaga\n\nK\n\n,\n\nKorenaga\n\nM\n\n,\n\nFurukawa\n\nM\n\n,\n\nYamasaki\n\nT\n\n,\n\nSakaida\n\nI\n\n.\n\nUsefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images\n\n.\n\nJ Gastroenterol\n\n.\n\n2009\n\n;\n\n44\n\n(\n\n7\n\n):\n\n733\n\n–\n\n41\n\n. .\n\n48.\n\nTanaka\n\nH\n\n,\n\nIijima\n\nH\n\n,\n\nHigashiura\n\nA\n\n,\n\nYoh\n\nK\n\n,\n\nIshii\n\nA\n\n,\n\nTakashima\n\nT\n\n, et al\n\nNew malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography\n\n.\n\nJ Gastroenterol\n\n.\n\n2014\n\n;\n\n49\n\n(\n\n4\n\n):\n\n755\n\n–\n\n63\n\n. .\n\n49.\n\nMinami\n\nT\n\n,\n\nMinami\n\nY\n\n,\n\nChishina\n\nH\n\n,\n\nArizumi\n\nT\n\n,\n\nTakita\n\nM\n\n,\n\nKitai\n\nS\n\n, et al\n\nCombination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging\n\n.\n\nOncology\n\n.\n\n2014\n\n;\n\n87\n\n(\n\nSuppl 1\n\n):\n\n55\n\n–\n\n62\n\n. .\n\n50.\n\nManini\n\nMA\n\n,\n\nSangiovanni\n\nA\n\n,\n\nFornari\n\nF\n\n,\n\nPiscaglia\n\nF\n\n,\n\nBiolato\n\nM\n\n,\n\nFanigliulo\n\nL\n\n, et al\n\nClinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma\n\n.\n\nJ Hepatol\n\n.\n\n2014\n\n;\n\n60\n\n(\n\n5\n\n):\n\n995\n\n–\n\n1001\n\n. .\n\n51.\n\nMurakami\n\nT\n\n,\n\nKim\n\nT\n\n,\n\nTakamura\n\nM\n\n,\n\nHori\n\nM\n\n,\n\nTakahashi\n\nS\n\n,\n\nFederle\n\nMP\n\n, et al\n\nHypervascular hepatocellular carcinoma: detection with double arterial phase multi-detector row helical CT\n\n.\n\nRadiology\n\n.\n\n2001\n\n;\n\n218\n\n(\n\n3\n\n):\n\n763\n\n–\n\n7\n\n. .\n\n52.\n\nKadoya\n\nM\n\n,\n\nMatsui\n\nO\n\n,\n\nTakashima\n\nT\n\n,\n\nNonomura\n\nA\n\n.\n\nHepatocellular carcinoma: correlation of MR imaging and histopathologic findings\n\n.\n\nRadiology\n\n.\n\n1992\n\n;\n\n183\n\n(\n\n3\n\n):\n\n819\n\n–\n\n25\n\n. .\n\n53.\n\nMotosugi\n\nU\n\n,\n\nIchikawa\n\nT\n\n,\n\nSou\n\nH\n\n,\n\nSano\n\nK\n\n,\n\nTominaga\n\nL\n\n,\n\nMuhi\n\nA\n\n, et al\n\nDistinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging\n\n.\n\nRadiology\n\n.\n\n2010\n\n;\n\n256\n\n(\n\n1\n\n):\n\n151\n\n–\n\n8\n\n. .\n\n54.\n\nSofue\n\nK\n\n,\n\nMarin\n\nD\n\n,\n\nJaffe\n\nTA\n\n,\n\nNelson\n\nRC\n\n,\n\nBashir\n\nMR\n\n.\n\nCan combining triple-arterial phase acquisition with fluoroscopic triggering provide both optimal early and late hepatic arterial phase images during gadoxetic acid-enhanced MRI?\n\nJ Magn Reson Imaging\n\n.\n\n2016\n\n;\n\n43\n\n(\n\n5\n\n):\n\n1073\n\n–\n\n81\n\n. .\n\n55.\n\nLee\n\nYJ\n\n,\n\nLee\n\nJM\n\n,\n\nLee\n\nJS\n\n,\n\nLee\n\nHY\n\n,\n\nPark\n\nBH\n\n,\n\nKim\n\nYH\n\n, et al\n\nHepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis\n\n.\n\nRadiology\n\n.\n\n2015\n\n;\n\n275\n\n(\n\n1\n\n):\n\n97\n\n–\n\n109\n\n. .\n\n56.\n\nImai\n\nY\n\n,\n\nMurakami\n\nT\n\n,\n\nYoshida\n\nS\n\n,\n\nNishikawa\n\nM\n\n,\n\nOhsawa\n\nM\n\n,\n\nTokunaga\n\nK\n\n, et al\n\nSuperparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading\n\n.\n\nHepatology\n\n.\n\n2000\n\n;\n\n32\n\n(\n\n2\n\n):\n\n205\n\n–\n\n12\n\n. .\n\n57.\n\nDuncan\n\nJK\n\n,\n\nMa\n\nN\n\n,\n\nVreugdenburg\n\nTD\n\n,\n\nCameron\n\nAL\n\n,\n\nMaddern\n\nG\n\n.\n\nGadoxetic acid-enhanced MRI for the characterization of hepatocellular carcinoma: a systematic review and meta-analysis\n\n.\n\nJ Magn Reson Imaging\n\n.\n\n2017\n\n;\n\n45\n\n(\n\n1\n\n):\n\n281\n\n–\n\n90\n\n. .\n\n58.\n\nKitao\n\nA\n\n,\n\nMatsui\n\nO\n\n,\n\nYoneda\n\nN\n\n,\n\nKozaka\n\nK\n\n,\n\nKobayashi\n\nS\n\n,\n\nSanada\n\nJ\n\n, et al\n\nHepatocellular carcinoma with beta-catenin mutation: imaging and pathologic characteristics\n\n.\n\nRadiology\n\n.\n\n2015\n\n;\n\n275\n\n:\n\n708\n\n–\n\n17\n\n.\n\n59.\n\nKudo\n\nM\n\n.\n\nGd-EOB-DTPA-MRI could predict WNT/β-catenin mutation and resistance to immune checkpoint inhibitor therapy in hepatocellular carcinoma\n\n.\n\nLiver Cancer\n\n.\n\n2020 Sep\n\n;\n\n9\n\n(\n\n5\n\n):\n\n479\n\n–\n\n90\n\n.\n\n60.\n\nSano\n\nK\n\n,\n\nIchikawa\n\nT\n\n,\n\nMotosugi\n\nU\n\n,\n\nSou\n\nH\n\n,\n\nMuhi\n\nAM\n\n,\n\nMatsuda\n\nM\n\n, et al\n\nImaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging\n\n.\n\nRadiology\n\n.\n\n2011\n\n;\n\n261\n\n(\n\n3\n\n):\n\n834\n\n–\n\n44\n\n. .\n\n61.\n\nGoshima\n\nS\n\n,\n\nKanematsu\n\nM\n\n,\n\nWatanabe\n\nH\n\n,\n\nKondo\n\nH\n\n,\n\nShiratori\n\nY\n\n,\n\nOnozuka\n\nM\n\n, et al\n\nHepatic hemangioma and metastasis: differentiation with gadoxetate disodium-enhanced 3-T MRI\n\n.\n\nAJR Am J Roentgenol\n\n.\n\n2010\n\n;\n\n195\n\n(\n\n4\n\n):\n\n941\n\n–\n\n6\n\n. .\n\n62.\n\nMatsui\n\nO\n\n,\n\nKadoya\n\nM\n\n,\n\nKameyama\n\nT\n\n,\n\nYoshikawa\n\nJ\n\n,\n\nTakashima\n\nT\n\n,\n\nNakanuma\n\nY\n\n, et al\n\nBenign and malignant nodules in cirrhotic livers: distinction based on blood supply\n\n.\n\nRadiology\n\n.\n\n1991\n\n;\n\n178\n\n(\n\n2\n\n):\n\n493\n\n–\n\n7\n\n. .\n\n63.\n\nHayashi\n\nM\n\n,\n\nMatsui\n\nO\n\n,\n\nUeda\n\nK\n\n,\n\nKawamori\n\nY\n\n,\n\nKadoya\n\nM\n\n,\n\nYoshikawa\n\nJ\n\n, et al\n\nCorrelation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium\n\n.\n\nAJR Am J Roentgenol\n\n.\n\n1999\n\n;\n\n172\n\n(\n\n4\n\n):\n\n969\n\n–\n\n76\n\n. .\n\n64.\n\nNarita\n\nM\n\n,\n\nHatano\n\nE\n\n,\n\nArizono\n\nS\n\n,\n\nMiyagawa-Hayashino\n\nA\n\n,\n\nIsoda\n\nH\n\n,\n\nKitamura\n\nK\n\n, et al\n\nExpression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma\n\n.\n\nJ Gastroenterol\n\n.\n\n2009\n\n;\n\n44\n\n(\n\n7\n\n):\n\n793\n\n–\n\n8\n\n. .\n\n65.\n\nKitao\n\nA\n\n,\n\nMatsui\n\nO\n\n,\n\nYoneda\n\nN\n\n,\n\nKozaka\n\nK\n\n,\n\nShinmura\n\nR\n\n,\n\nKoda\n\nW\n\n, et al\n\nThe uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging\n\n.\n\nEur Radiol\n\n.\n\n2011\n\n;\n\n21\n\n(\n\n10\n\n):\n\n2056\n\n–\n\n66\n\n. .\n\n66.\n\nKogita\n\nS\n\n,\n\nImai\n\nY\n\n,\n\nOkada\n\nM\n\n,\n\nKim\n\nT\n\n,\n\nOnishi\n\nH\n\n,\n\nTakamura\n\nM\n\n, et al\n\nGd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow\n\n.\n\nEur Radiol\n\n.\n\n2010\n\n;\n\n20\n\n(\n\n10\n\n):\n\n2405\n\n–\n\n13\n\n. .\n\n67.\n\nKumada\n\nT\n\n,\n\nToyoda\n\nH\n\n,\n\nTada\n\nT\n\n,\n\nSone\n\nY\n\n,\n\nFujimori\n\nM\n\n,\n\nOgawa\n\nS\n\n, et al\n\nEvolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI\n\n.\n\nAJR Am J Roentgenol\n\n.\n\n2011\n\n;\n\n197\n\n(\n\n1\n\n):\n\n58\n\n–\n\n63\n\n. .\n\n68.\n\nMotosugi\n\nU\n\n,\n\nIchikawa\n\nT\n\n,\n\nSano\n\nK\n\n,\n\nSou\n\nH\n\n,\n\nOnohara\n\nK\n\n,\n\nMuhi\n\nA\n\n, et al\n\nOutcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease\n\n.\n\nJ Magn Reson Imaging\n\n.\n\n2011\n\n;\n\n34\n\n(\n\n1\n\n):\n\n88\n\n–\n\n94\n\n. .\n\n69.\n\nHyodo\n\nT\n\n,\n\nMurakami\n\nT\n\n,\n\nImai\n\nY\n\n,\n\nOkada\n\nM\n\n,\n\nHori\n\nM\n\n,\n\nKagawa\n\nY\n\n, et al\n\nHypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma\n\n.\n\nRadiology\n\n.\n\n2013\n\n;\n\n266\n\n(\n\n2\n\n):\n\n480\n\n–\n\n90\n\n. .\n\n70.\n\nEASL Clinical Practice Guidelines\n\n.\n\nManagement of hepatocellular carcinoma\n\n.\n\nJ Hepatol\n\n.\n\n2018\n\n;\n\n69\n\n:\n\n182\n\n–\n\n236\n\n.\n\n71.\n\nMarrero\n\nJA\n\n,\n\nKulik\n\nLM\n\n,\n\nSirlin\n\nCB\n\n,\n\nZhu\n\nAX\n\n,\n\nFinn\n\nRS\n\n,\n\nAbecassis\n\nMM\n\n, et al\n\nDiagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases\n\n.\n\nHepatology\n\n.\n\n2018\n\n;\n\n68\n\n(\n\n2\n\n):\n\n723\n\n–\n\n50\n\n. .\n\n72.\n\nTakayama\n\nT\n\n,\n\nMakuuchi\n\nM\n\n,\n\nHirohashi\n\nS\n\n,\n\nSakamoto\n\nM\n\n,\n\nYamamoto\n\nJ\n\n,\n\nShimada\n\nK\n\n, et al\n\nEarly hepatocellular carcinoma as an entity with a high rate of surgical cure\n\n.\n\nHepatology\n\n.\n\n1998\n\n;\n\n28\n\n(\n\n5\n\n):\n\n1241\n\n–\n\n6\n\n. .\n\n73.\n\nMidorikawa\n\nY\n\n,\n\nTakayama\n\nT\n\n,\n\nShimada\n\nK\n\n,\n\nNakayama\n\nH\n\n,\n\nHigaki\n\nT\n\n,\n\nMoriguchi\n\nM\n\n, et al\n\nMarginal survival benefit in the treatment of early hepatocellular carcinoma\n\n.\n\nJ Hepatol\n\n.\n\n2013\n\n;\n\n58\n\n(\n\n2\n\n):\n\n306\n\n–\n\n11\n\n. .\n\n74.\n\nKudo\n\nM\n\n,\n\nMatsui\n\nO\n\n,\n\nIzumi\n\nN\n\n,\n\nIijima\n\nH\n\n,\n\nKadoya\n\nM\n\n,\n\nImai\n\nY\n\n.\n\nSurveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the Liver Cancer Study Group of Japan: 2014 update\n\n.\n\nOncology\n\n.\n\n2014\n\n;\n\n87\n\n(\n\nSuppl 1\n\n):\n\n7\n\n–\n\n21\n\n.\n\n75.\n\nOhama\n\nH\n\n,\n\nImai\n\nY\n\n,\n\nNakashima\n\nO\n\n,\n\nKogita\n\nS\n\n,\n\nTakamura\n\nM\n\n,\n\nHori\n\nM\n\n, et al\n\nImages of Sonazoid-enhanced ultrasonography in multistep hepatocarcinogenesis: comparison with Gd-EOB-DTPA-enhanced MRI\n\n.\n\nJ Gastroenterol\n\n.\n\n2014\n\n;\n\n49\n\n(\n\n6\n\n):\n\n1081\n\n–\n\n93\n\n. .\n\n76.\n\nInoue\n\nT\n\n,\n\nHyodo\n\nT\n\n,\n\nKorenaga\n\nK\n\n,\n\nMurakami\n\nT\n\n,\n\nImai\n\nY\n\n,\n\nHigaki\n\nA\n\n, et al\n\nKupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study\n\n.\n\nJ Gastroenterol\n\n.\n\n2016\n\n;\n\n51\n\n(\n\n2\n\n):\n\n144\n\n–\n\n52\n\n. .\n\n77.\n\nOmata\n\nM\n\n,\n\nCheng\n\nAL\n\n,\n\nKokudo\n\nN\n\n,\n\nKudo\n\nM\n\n,\n\nLee\n\nJM\n\n,\n\nJia\n\nJ\n\n, et al\n\nAsia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update\n\n.\n\nHepatol Int\n\n.\n\n2017\n\n;\n\n11\n\n(\n\n4\n\n):\n\n317\n\n–\n\n70\n\n. .\n\n78.\n\nOkuda\n\nK\n\n,\n\nOhtsuki\n\nT\n\n,\n\nObata\n\nH\n\n,\n\nTomimatsu\n\nM\n\n,\n\nOkazaki\n\nN\n\n,\n\nHasegawa\n\nH\n\n, et al\n\nNatural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients\n\n.\n\nCancer\n\n.\n\n1985\n\n;\n\n56\n\n(\n\n4\n\n):\n\n918\n\n–\n\n28\n\n. .\n\n79.\n\nLlovet\n\nJM\n\n,\n\nBrú\n\nC\n\n,\n\nBruix\n\nJ\n\n.\n\nPrognosis of hepatocellular carcinoma: the BCLC staging classification\n\n.\n\nSemin Liver Dis\n\n.\n\n1999\n\n;\n\n19\n\n(\n\n3\n\n):\n\n329\n\n–\n\n38\n\n. .\n\n80.\n\nForner\n\nA\n\n,\n\nReig\n\nM\n\n,\n\nBruix\n\nJ\n\n.\n\nHepatocellular carcinoma\n\n.\n\nLancet\n\n.\n\n2018\n\n;\n\n391\n\n(\n\n10127\n\n):\n\n1301\n\n–\n\n14\n\n. .\n\n81.\n\nA new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators\n\n.\n\nHepatology\n\n.\n\n1998\n\n;\n\n28\n\n(\n\n3\n\n):\n\n751\n\n–\n\n5\n\n.\n\n82.\n\nKudo\n\nM\n\n,\n\nChung\n\nH\n\n,\n\nOsaki\n\nY\n\n.\n\nPrognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)\n\n.\n\nJ Gastroenterol\n\n.\n\n2003\n\n;\n\n38\n\n(\n\n3\n\n):\n\n207\n\n–\n\n15\n\n. .\n\n83.\n\nKudo\n\nM\n\n,\n\nChung\n\nH\n\n,\n\nHaji\n\nS\n\n,\n\nOsaki\n\nY\n\n,\n\nOka\n\nH\n\n,\n\nSeki\n\nT\n\n, et al\n\nValidation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score\n\n.\n\nHepatology\n\n.\n\n2004\n\n;\n\n40\n\n(\n\n6\n\n):\n\n1396\n\n–\n\n405\n\n. .\n\n84.\n\nNanashima\n\nA\n\n,\n\nSumida\n\nY\n\n,\n\nAbo\n\nT\n\n,\n\nShindou\n\nH\n\n,\n\nFukuoka\n\nH\n\n,\n\nTakeshita\n\nH\n\n, et al\n\nModified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy\n\n.\n\nJ Gastroenterol\n\n.\n\n2006\n\n;\n\n41\n\n(\n\n3\n\n):\n\n250\n\n–\n\n6\n\n. .\n\n85.\n\nIkai\n\nI\n\n,\n\nTakayasu\n\nK\n\n,\n\nOmata\n\nM\n\n,\n\nOkita\n\nK\n\n,\n\nNakanuma\n\nY\n\n,\n\nMatsuyama\n\nY\n\n, et al\n\nA modified Japan Integrated Stage score for prognostic assessment in patients with hepatocellular carcinoma\n\n.\n\nJ Gastroenterol\n\n.\n\n2006\n\n;\n\n41\n\n(\n\n9\n\n):\n\n884\n\n–\n\n92\n\n. .\n\n86.\n\nKitai\n\nS\n\n,\n\nKudo\n\nM\n\n,\n\nMinami\n\nY\n\n,\n\nUeshima\n\nK\n\n,\n\nChung\n\nH\n\n,\n\nHagiwara\n\nS\n\n, et al\n\nA new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score\n\n.\n\nIntervirology\n\n.\n\n2008\n\n;\n\n51\n\n:\n\nS86\n\n–\n\n94\n\n.\n\n87.\n\nTateishi\n\nR\n\n,\n\nYoshida\n\nH\n\n,\n\nShiina\n\nS\n\n,\n\nImamura\n\nH\n\n,\n\nHasegawa\n\nK\n\n,\n\nTeratani\n\nT\n\n, et al\n\nProposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients\n\n.\n\nGut\n\n.\n\n2005\n\n;\n\n54\n\n(\n\n3\n\n):\n\n419\n\n–\n\n25\n\n. .\n\n88.\n\nToyoda\n\nH\n\n,\n\nKumada\n\nT\n\n,\n\nOsaki\n\nY\n\n,\n\nOka\n\nH\n\n,\n\nUrano\n\nF\n\n,\n\nKudo\n\nM\n\n, et al\n\nStaging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers\n\n.\n\nClin Gastroenterol Hepatol\n\n.\n\n2006\n\n;\n\n4\n\n(\n\n12\n\n):\n\n1528\n\n–\n\n36\n\n. .\n\n89.\n\nToyoda\n\nH\n\n,\n\nTada\n\nT\n\n,\n\nJohnson\n\nPJ\n\n,\n\nIzumi\n\nN\n\n,\n\nKadoya\n\nM\n\n,\n\nKaneko\n\nS\n\n, et al\n\nValidation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey\n\n.\n\nJ Gastroenterol\n\n.\n\n2017\n\n;\n\n52\n\n:\n\n1112\n\n–\n\n21\n\n. .\n\n90.\n\nCaviglia\n\nGP\n\n,\n\nAbate\n\nML\n\n,\n\nPetrini\n\nE\n\n,\n\nGaia\n\nS\n\n,\n\nRizzetto\n\nM\n\n,\n\nSmedile\n\nA\n\n.\n\nHighly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection\n\n.\n\nHepatol Res\n\n.\n\n2016\n\n;\n\n46\n\n(\n\n3\n\n):\n\nE130\n\n–\n\n5\n\n. .\n\n91.\n\nHiraoka\n\nA\n\n,\n\nKumada\n\nT\n\n,\n\nMichitaka\n\nK\n\n,\n\nToyoda\n\nH\n\n,\n\nTada\n\nT\n\n,\n\nUeki\n\nH\n\n, et al\n\nUsefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma\n\n.\n\nJ Gastroenterol Hepatol\n\n.\n\n2016\n\n;\n\n31\n\n(\n\n5\n\n):\n\n1031\n\n–\n\n6\n\n. .\n\n92.\n\nHiraoka\n\nA\n\n,\n\nKumada\n\nT\n\n,\n\nTsuji\n\nK\n\n,\n\nTakaguchi\n\nK\n\n,\n\nItobayashi\n\nE\n\n,\n\nKariyama\n\nK\n\n, et al\n\nValidation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: a multicenter analysis\n\n.\n\nLiver Cancer\n\n.\n\n2019\n\n;\n\n8\n\n(\n\n2\n\n):\n\n121\n\n–\n\n9\n\n. .\n\n93.\n\nYau\n\nT\n\n,\n\nTang\n\nVY\n\n,\n\nYao\n\nTJ\n\n,\n\nFan\n\nST\n\n,\n\nLo\n\nCM\n\n,\n\nPoon\n\nRT\n\n.\n\nDevelopment of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma\n\n.\n\nGastroenterology\n\n.\n\n2014\n\n;\n\n146\n\n(\n\n7\n\n):\n\n1691\n\n–\n\n700.e3\n\n. .\n\n94.\n\nLiu\n\nPH\n\n,\n\nHsu\n\nCY\n\n,\n\nLee\n\nYH\n\n,\n\nSu\n\nCW\n\n,\n\nHsia\n\nCY\n\n,\n\nHuang\n\nYH\n\n, et al\n\nHong Kong liver cancer staging system is associated with better performance for hepatocellular carcinoma: special emphasis on viral etiology\n\n.\n\nMedicine\n\n.\n\n2015\n\n;\n\n94\n\n:\n\ne1772\n\n.\n\n95.\n\nHiraoka\n\nA\n\n,\n\nKumada\n\nT\n\n,\n\nKudo\n\nM\n\n,\n\nHirooka\n\nM\n\n,\n\nTsuji\n\nK\n\n,\n\nItobayashi\n\nE\n\n, et al\n\nAlbumin-Bilirubin (ALBI) Grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications\n\n.\n\nLiver Cancer\n\n.\n\n2017\n\n;\n\n6\n\n(\n\n3\n\n):\n\n204\n\n–\n\n15\n\n. .\n\n96.\n\nKudo\n\nM\n\n,\n\nIzumi\n\nN\n\n,\n\nKubo\n\nS\n\n,\n\nKokudo\n\nN\n\n,\n\nSakamoto\n\nM\n\n,\n\nShiina\n\nS\n\n, et al\n\nReport of the 20th Nationwide follow-up survey of primary liver cancer in Japan\n\n.\n\nHepatol Res\n\n.\n\n2020\n\n;\n\n50\n\n(\n\n1\n\n):\n\n15\n\n–\n\n46\n\n. .\n\n97.\n\nKakeji\n\nY\n\n,\n\nTakahashi\n\nA\n\n,\n\nUdagawa\n\nH\n\n,\n\nUnno\n\nM\n\n,\n\nEndo\n\nI\n\n,\n\nKunisaki\n\nC\n\n, et al\n\nSurgical outcomes in gastroenterological surgery in Japan: report of National Clinical database 2011–2016\n\n.\n\nAnn Gastroenterol Surg\n\n.\n\n2018\n\n;\n\n2\n\n(\n\n1\n\n):\n\n37\n\n–\n\n54\n\n. .\n\n98.\n\nIshizawa\n\nT\n\n,\n\nHasegawa\n\nK\n\n,\n\nAoki\n\nT\n\n,\n\nTakahashi\n\nM\n\n,\n\nInoue\n\nY\n\n,\n\nSano\n\nK\n\n, et al\n\nNeither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma\n\n.\n\nGastroenterology\n\n.\n\n2008\n\n;\n\n134\n\n(\n\n7\n\n):\n\n1908\n\n–\n\n16\n\n. .\n\n99.\n\nShiina\n\nS\n\n,\n\nTeratani\n\nT\n\n,\n\nObi\n\nS\n\n,\n\nSato\n\nS\n\n,\n\nTateishi\n\nR\n\n,\n\nFujishima\n\nT\n\n, et al\n\nA randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma\n\n.\n\nGastroenterology\n\n.\n\n2005\n\n;\n\n129\n\n(\n\n1\n\n):\n\n122\n\n–\n\n30\n\n. .\n\n100.\n\nChen\n\nMS\n\n,\n\nLi\n\nJQ\n\n,\n\nZheng\n\nY\n\n,\n\nGuo\n\nRP\n\n,\n\nLiang\n\nHH\n\n,\n\nZhang\n\nYQ\n\n, et al\n\nA prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma\n\n.\n\nAnn Surg\n\n.\n\n2006\n\n;\n\n243\n\n(\n\n3\n\n):\n\n321\n\n–\n\n8\n\n. .\n\n101.\n\nHuang\n\nJ\n\n,\n\nYan\n\nL\n\n,\n\nCheng\n\nZ\n\n,\n\nWu\n\nH\n\n,\n\nDu\n\nL\n\n,\n\nWang\n\nJ\n\n, et al\n\nA randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria\n\n.\n\nAnn Surg\n\n.\n\n2010\n\n;\n\n252\n\n(\n\n6\n\n):\n\n903\n\n–\n\n12\n\n. .\n\n102.\n\nIzumi\n\nN\n\n,\n\nHasegawa\n\nK\n\n,\n\nNishioka\n\nY\n\n,\n\nTakayama\n\nT\n\n,\n\nYamanaka\n\nN\n\n,\n\nMasatoshi Kudo\n\nM\n\n, et al\n\nA multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial)\n\n.\n\nJ Clin Oncol\n\n.\n\n2019\n\n;\n\n37\n\n(\n\nSuppl 15\n\n):\n\n4002\n\n. [ASCO 2019, LBA]. .\n\n103.\n\nNouso\n\nK\n\n,\n\nKariyama\n\nK\n\n,\n\nNakamura\n\nS\n\n,\n\nOonishi\n\nA\n\n,\n\nWakuta\n\nA\n\n,\n\nOyama\n\nA\n\n, et al\n\nApplication of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma\n\n.\n\nJ Gastroenterol Hepatol\n\n.\n\n2017\n\n;\n\n32\n\n(\n\n3\n\n):\n\n695\n\n–\n\n700\n\n. .\n\n104.\n\nBolondi\n\nL\n\n,\n\nBurroughs\n\nA\n\n,\n\nDufour\n\nJF\n\n,\n\nGalle\n\nPR\n\n,\n\nMazzaferro\n\nV\n\n,\n\nPiscaglia\n\nF\n\n, et al\n\nHeterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions\n\n.\n\nSemin Liver Dis\n\n.\n\n2012\n\n;\n\n32\n\n(\n\n4\n\n):\n\n348\n\n–\n\n59\n\n. .\n\n105.\n\nYin\n\nXY\n\n,\n\nXie\n\nXY\n\n,\n\nLu\n\nMD\n\n,\n\nXu\n\nHX\n\n,\n\nXu\n\nZF\n\n,\n\nKuang\n\nM\n\n, et al\n\nPercutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors\n\n.\n\nCancer\n\n.\n\n2009\n\n;\n\n115\n\n(\n\n9\n\n):\n\n1914\n\n–\n\n23\n\n. .\n\n106.\n\nShen\n\nA\n\n,\n\nZhang\n\nH\n\n,\n\nTang\n\nC\n\n,\n\nChen\n\nY\n\n,\n\nWang\n\nY\n\n,\n\nZhang\n\nC\n\n, et al\n\nSystematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm\n\n.\n\nJ Gastroenterol Hepatol\n\n.\n\n2013\n\n;\n\n28\n\n(\n\n5\n\n):\n\n793\n\n–\n\n800\n\n. .\n\n107.\n\nKoda\n\nM\n\n,\n\nMurawaki\n\nY\n\n,\n\nHirooka\n\nY\n\n,\n\nKitamoto\n\nM\n\n,\n\nOno\n\nM\n\n,\n\nSakaeda\n\nH\n\n, et al\n\nComplications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: an analysis of 16 346 treated nodules in 13 283 patients\n\n.\n\nHepatol Res\n\n.\n\n2012\n\n;\n\n42\n\n(\n\n11\n\n):\n\n1058\n\n–\n\n64\n\n. .\n\n108.\n\nMaeda\n\nM\n\n,\n\nSaeki\n\nI\n\n,\n\nSakaida\n\nI\n\n,\n\nAikata\n\nH\n\n,\n\nAraki\n\nY\n\n,\n\nOgawa\n\nC\n\n, et al\n\nComplications after radiofrequency ablation for hepatocellular carcinoma: a multicenter study involving 9,411 Japanese patients\n\n.\n\nLiver Cancer\n\n.\n\n2020\n\n;\n\n9\n\n(\n\n1\n\n):\n\n50\n\n–\n\n62\n\n. .\n\n109.\n\nKasugai\n\nH\n\n,\n\nOsaki\n\nY\n\n,\n\nOka\n\nH\n\n,\n\nKudo\n\nM\n\n,\n\nSeki\n\nT\n\n.\n\nSevere complications of radiofrequency ablation therapy for hepatocellular carcinoma: an analysis of 3,891 ablations in 2,614 patients\n\n.\n\nOncology\n\n.\n\n2007\n\n;\n\n72\n\n(\n\nSuppl 1\n\n):\n\n72\n\n–\n\n5\n\n. .\n\n110.\n\nYamada\n\nR\n\n,\n\nSato\n\nM\n\n,\n\nKawabata\n\nM\n\n,\n\nNakatsuka\n\nH\n\n,\n\nNakamura\n\nK\n\n,\n\nTakashima\n\nS\n\n.\n\nHepatic artery embolization in 120 patients with unresectable hepatoma\n\n.\n\nRadiology\n\n.\n\n1983\n\n;\n\n148\n\n(\n\n2\n\n):\n\n397\n\n–\n\n401\n\n. .\n\n111.\n\nOhishi\n\nH\n\n,\n\nUchida\n\nH\n\n,\n\nYoshimura\n\nH\n\n,\n\nOhue\n\nS\n\n,\n\nUeda\n\nJ\n\n,\n\nKatsuragi\n\nM\n\n, et al\n\nHepatocellular carcinoma detected by iodized oil. Use of anticancer agents\n\n.\n\nRadiology\n\n.\n\n1985\n\n;\n\n154\n\n(\n\n1\n\n):\n\n25\n\n–\n\n9\n\n. .\n\n112.\n\nMatsui\n\nO\n\n,\n\nMiyayama\n\nS\n\n,\n\nSanada\n\nJ\n\n,\n\nKobayashi\n\nS\n\n,\n\nKhoda\n\nW\n\n,\n\nMinami\n\nT\n\n, et al\n\nInterventional oncology: new options for interstitial treatments and intravascular approaches: superselective TACE using iodized oil for HCC: rationale, technique and outcome\n\n.\n\nJ Hepatobiliary Pancreat Sci\n\n.\n\n2010\n\n;\n\n17\n\n(\n\n4\n\n):\n\n407\n\n–\n\n9\n\n. .\n\n113.\n\nMiyayama\n\nS\n\n,\n\nMatsui\n\nO\n\n.\n\nSuperselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome\n\n.\n\nJ Vasc Interv Radiol\n\n.\n\n2016\n\n;\n\n27\n\n(\n\n9\n\n):\n\n1269\n\n–\n\n78\n\n. .\n\n114.\n\nMiyayama\n\nS\n\n,\n\nMatsui\n\nO\n\n,\n\nYamashiro\n\nM\n\n,\n\nRyu\n\nY\n\n,\n\nKaito\n\nK\n\n,\n\nOzaki\n\nK\n\n, et al\n\nUltraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil\n\n.\n\nJ Vasc Interv Radiol\n\n.\n\n2007\n\n;\n\n18\n\n(\n\n3\n\n):\n\n365\n\n–\n\n76\n\n. .\n\n115.\n\nLammer\n\nJ\n\n,\n\nMalagari\n\nK\n\n,\n\nVogl\n\nT\n\n,\n\nPilleul\n\nF\n\n,\n\nDenys\n\nA\n\n,\n\nWatkinson\n\nA\n\n, et al\n\nProspective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study\n\n.\n\nCardiovasc Intervent Radiol\n\n.\n\n2010\n\n;\n\n33\n\n(\n\n1\n\n):\n\n41\n\n–\n\n52\n\n. .\n\n116.\n\nNouso\n\nK\n\n,\n\nKokudo\n\nN\n\n,\n\nTanaka\n\nM\n\n,\n\nKuromatsu\n\nR\n\n,\n\nNishikawa\n\nH\n\n,\n\nToyoda\n\nH\n\n, et al\n\nTreatment of hepatocellular carcinoma with Child-Pugh C cirrhosis\n\n.\n\nOncology\n\n.\n\n2014\n\n;\n\n87\n\n(\n\nSuppl 1\n\n):\n\n99\n\n–\n\n103\n\n. .\n\n117.\n\nKitai\n\nS\n\n,\n\nKudo\n\nM\n\n,\n\nNishida\n\nN\n\n,\n\nIzumi\n\nN\n\n,\n\nSakamoto\n\nM\n\n,\n\nMatsuyama\n\nY\n\n, et al\n\nSurvival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis\n\n.\n\nLiver Cancer\n\n.\n\n2016\n\n;\n\n5\n\n(\n\n3\n\n):\n\n175\n\n–\n\n89\n\n. .\n\n118.\n\nKudo\n\nM\n\n,\n\nOsaki\n\nY\n\n,\n\nMatsunaga\n\nT\n\n,\n\nKasugai\n\nH\n\n,\n\nOka\n\nH\n\n,\n\nSeki\n\nT\n\n.\n\nHepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments\n\n.\n\nDig Dis\n\n.\n\n2013\n\n;\n\n31\n\n(\n\n5–6\n\n):\n\n490\n\n–\n\n8\n\n. .\n\n119.\n\nNouso\n\nK\n\n,\n\nIto\n\nY\n\n,\n\nKuwaki\n\nK\n\n,\n\nKobayashi\n\nY\n\n,\n\nNakamura\n\nS\n\n,\n\nOhashi\n\nY\n\n, et al\n\nPrognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis\n\n.\n\nBr J Cancer\n\n.\n\n2008\n\n;\n\n98\n\n(\n\n7\n\n):\n\n1161\n\n–\n\n5\n\n. .\n\n120.\n\nNishikawa\n\nH\n\n,\n\nKita\n\nR\n\n,\n\nKimura\n\nT\n\n,\n\nOhara\n\nY\n\n,\n\nTakeda\n\nH\n\n,\n\nSakamoto\n\nA\n\n, et al\n\nClinical efficacy of non-transplant therapies in patients with hepatocellular carcinoma with Child-Pugh C liver cirrhosis\n\n.\n\nAnticancer Res\n\n.\n\n2014\n\n;\n\n34\n\n(\n\n6\n\n):\n\n3039\n\n–\n\n44\n\n.\n\n121.\n\nToyoda\n\nH\n\n,\n\nKumada\n\nT\n\n,\n\nKiriyama\n\nS\n\n,\n\nSone\n\nY\n\n,\n\nTanikawa\n\nM\n\n,\n\nHisanaga\n\nY\n\n, et al\n\nImpact of tumor factors on the prognosis of patients with advanced cirrhosis (Child-Pugh class C) and hepatocellular carcinoma\n\n.\n\nJ Gastroenterol Hepatol\n\n.\n\n2005\n\n;\n\n20\n\n(\n\n6\n\n):\n\n963\n\n–\n\n5\n\n. .\n\n122.\n\nGolfieri\n\nR\n\n,\n\nGiampalma\n\nE\n\n,\n\nRenzulli\n\nM\n\n,\n\nCioni\n\nR\n\n,\n\nBargellini\n\nI\n\n,\n\nBartolozzi\n\nC\n\n, et al\n\nRandomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma\n\n.\n\nBr J Cancer\n\n.\n\n2014\n\n;\n\n111\n\n(\n\n2\n\n):\n\n255\n\n–\n\n64\n\n. .\n\n123.\n\nFacciorusso\n\nA\n\n,\n\nDi Maso\n\nM\n\n,\n\nMuscatiello\n\nN\n\n.\n\nDrug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis\n\n.\n\nDig Liver Dis\n\n.\n\n2016\n\n;\n\n48\n\n:\n\n571\n\n–\n\n7\n\n.\n\n124.\n\nIkeda\n\nM\n\n,\n\nInaba\n\nY\n\n,\n\nTanaka\n\nT\n\n,\n\nSugawara\n\nS\n\n,\n\nKodama\n\nY\n\n,\n\nAramaki\n\nT\n\n, et al\n\nA prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: the JIVROSG-1302 PRESIDENT study\n\n.\n\nJ Clin Oncol\n\n.\n\n2020\n\n;\n\n38\n\n(\n\n15 Suppl\n\n):\n\n4518\n\n(suppl; abstr 4518). .\n\n125.\n\nWillett\n\nCG\n\n,\n\nBoucher\n\nY\n\n,\n\ndi Tomaso\n\nE\n\n,\n\nDuda\n\nDG\n\n,\n\nMunn\n\nLL\n\n,\n\nTong\n\nRT\n\n, et al\n\nDirect evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer\n\n.\n\nNat Med\n\n.\n\n2004\n\n;\n\n10\n\n(\n\n2\n\n):\n\n145\n\n–\n\n7\n\n. .\n\n126.\n\nYuan\n\nF\n\n,\n\nChen\n\nY\n\n,\n\nDellian\n\nM\n\n,\n\nSafabakhsh\n\nN\n\n,\n\nFerrara\n\nN\n\n,\n\nJain\n\nRK\n\n.\n\nTime-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody\n\n.\n\nProc Natl Acad Sci U S A\n\n.\n\n1996\n\n;\n\n93\n\n(\n\n25\n\n):\n\n14765\n\n–\n\n70\n\n. .\n\n127.\n\nJain\n\nRK\n\n.\n\nNormalization of tumor vasculature: an emerging concept in antiangiogenic therapy\n\n.\n\nScience\n\n.\n\n2005\n\n;\n\n307\n\n(\n\n5706\n\n):\n\n58\n\n–\n\n62\n\n. .\n\n128.\n\nKano\n\nMR\n\n,\n\nKomuta\n\nY\n\n,\n\nIwata\n\nC\n\n,\n\nOka\n\nM\n\n,\n\nShirai\n\nYT\n\n,\n\nMorishita\n\nY\n\n, et al\n\nComparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature\n\n.\n\nCancer Sci\n\n.\n\n2009\n\n;\n\n100\n\n(\n\n1\n\n):\n\n173\n\n–\n\n80\n\n. .\n\n129.\n\nJia\n\nZZ\n\n,\n\nJiang\n\nGM\n\n,\n\nFeng\n\nYL\n\n.\n\nSerum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer\n\n.\n\nChin Med Sci J\n\n.\n\n2011\n\n;\n\n26\n\n(\n\n3\n\n):\n\n158\n\n–\n\n62\n\n. .\n\n130.\n\nKudo\n\nM\n\n,\n\nUeshima\n\nK\n\n,\n\nIkeda\n\nM\n\n,\n\nTorimura\n\nT\n\n,\n\nTanabe\n\nN\n\n,\n\nAikata\n\nH\n\n, et al\n\nRandomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial\n\n.\n\nGut\n\n.\n\n2020 Aug\n\n;\n\n69\n\n(\n\n8\n\n):\n\n1492\n\n–\n\n501\n\n.\n\n131.\n\nKudo\n\nM\n\n,\n\nImanaka\n\nK\n\n,\n\nChida\n\nN\n\n,\n\nNakachi\n\nK\n\n,\n\nTak\n\nWY\n\n,\n\nTakayama\n\nT\n\n, et al\n\nPhase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma\n\n.\n\nEur J Cancer\n\n.\n\n2011\n\n;\n\n47\n\n(\n\n14\n\n):\n\n2117\n\n–\n\n27\n\n. .\n\n132.\n\nLencioni\n\nR\n\n,\n\nLlovet\n\nJM\n\n,\n\nHan\n\nG\n\n,\n\nTak\n\nWY\n\n,\n\nYang\n\nJ\n\n,\n\nGuglielmi\n\nA\n\n, et al\n\nSorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial\n\n.\n\nJ Hepatol\n\n.\n\n2016\n\n;\n\n64\n\n(\n\n5\n\n):\n\n1090\n\n–\n\n8\n\n. .\n\n133.\n\nMeyer\n\nT\n\n,\n\nFox\n\nR\n\n,\n\nMa\n\nYT\n\n,\n\nRoss\n\nPJ\n\n,\n\nJames\n\nMW\n\n,\n\nSturgess\n\nR\n\n, et al\n\nSorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial\n\n.\n\nLancet Gastroenterol Hepatol\n\n.\n\n2017\n\n;\n\n2\n\n(\n\n8\n\n):\n\n565\n\n–\n\n75\n\n. .\n\n134.\n\nKudo\n\nM\n\n,\n\nCheng\n\nA-L\n\n,\n\nPark\n\nJ-W\n\n,\n\nPark\n\nJH\n\n,\n\nLiang\n\nP-C\n\n,\n\nHidaka\n\nH\n\n, et al\n\nOrantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study\n\n.\n\nLancet Gastroenterol Hepatol\n\n.\n\n2018\n\n;\n\n3\n\n(\n\n1\n\n):\n\n37\n\n–\n\n46\n\n. .\n\n135.\n\nKudo\n\nM\n\n,\n\nHan\n\nG\n\n,\n\nFinn\n\nRS\n\n,\n\nPoon\n\nRT\n\n,\n\nBlanc\n\nJF\n\n,\n\nYan\n\nL\n\n, et al\n\nBrivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial\n\n.\n\nHepatology\n\n.\n\n2014\n\n;\n\n60\n\n(\n\n5\n\n):\n\n1697\n\n–\n\n707\n\n. .\n\n136.\n\nOgasawara\n\nS\n\n,\n\nChiba\n\nT\n\n,\n\nOoka\n\nY\n\n,\n\nKanogawa\n\nN\n\n,\n\nMotoyama\n\nT\n\n,\n\nSuzuki\n\nE\n\n, et al\n\nEfficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization\n\n.\n\nOncology\n\n.\n\n2014\n\n;\n\n87\n\n(\n\n6\n\n):\n\n330\n\n–\n\n41\n\n. .\n\n137.\n\nArizumi\n\nT\n\n,\n\nUeshima\n\nK\n\n,\n\nChishina\n\nH\n\n,\n\nKono\n\nM\n\n,\n\nTakita\n\nM\n\n,\n\nKitai\n\nS\n\n, et al\n\nValidation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ\n\n.\n\nOncology\n\n.\n\n2014\n\n;\n\n87\n\n(\n\nSuppl 1\n\n):\n\n32\n\n–\n\n6\n\n. .\n\n138.\n\nPeck-Radosavljevic\n\nM\n\n,\n\nRaoul\n\nJ\n\n,\n\nLee\n\nHC\n\n,\n\nKudo\n\nM\n\n,\n\nNakajima\n\nK\n\n,\n\nCheng\n\nAL\n\n.\n\nPractice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion\n\n. Global OPTIMIS exploratory analysis ILC 2019, FRI-494.\n\n139.\n\nKudo\n\nM\n\n,\n\nFinn\n\nRS\n\n,\n\nQin\n\nS\n\n,\n\nHan\n\nK-H\n\n,\n\nIkeda\n\nK\n\n,\n\nPiscaglia\n\nF\n\n, et al\n\nLenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial\n\n.\n\nLancet\n\n.\n\n2018\n\n;\n\n391\n\n(\n\n10126\n\n):\n\n1163\n\n–\n\n73\n\n. .\n\n140.\n\nYamashita\n\nT\n\n,\n\nKudo\n\nM\n\n,\n\nIkeda\n\nK\n\n,\n\nIzumi\n\nN\n\n,\n\nTateishi\n\nR\n\n,\n\nIkeda\n\nM\n\n, et al\n\nREFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset\n\n.\n\nJ Gastroenterol\n\n.\n\n2020\n\n;\n\n55\n\n(\n\n1\n\n):\n\n113\n\n–\n\n22\n\n. .\n\n141.\n\nUeshima\n\nK\n\n,\n\nNishida\n\nN\n\n,\n\nHagiwara\n\nS\n\n,\n\nAoki\n\nT\n\n,\n\nMinami\n\nT\n\n,\n\nChishina\n\nH\n\n, et al\n\nImpact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study\n\n.\n\nCancers\n\n.\n\n2019\n\n;\n\n11\n\n:\n\n952\n\n.\n\n142.\n\nRaoul\n\nJL\n\n,\n\nGilabert\n\nM\n\n,\n\nPiana\n\nG\n\n.\n\nHow to define transarterial chemoembolization failure or refractoriness: a European perspective\n\n.\n\nLiver Cancer\n\n.\n\n2014\n\n;\n\n3\n\n(\n\n2\n\n):\n\n119\n\n–\n\n24\n\n. .\n\n143.\n\nCheng\n\nAL\n\n,\n\nAmarapurkar\n\nD\n\n,\n\nChao\n\nY\n\n,\n\nChen\n\nPJ\n\n,\n\nGeschwind\n\nJF\n\n,\n\nGoh\n\nKL\n\n, et al\n\nRe-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: consensus recommendations and review by an International Expert Panel\n\n.\n\nLiver Int\n\n.\n\n2014\n\n;\n\n34\n\n(\n\n2\n\n):\n\n174\n\n–\n\n83\n\n. .\n\n144.\n\nArizumi\n\nT\n\n,\n\nUeshima\n\nK\n\n,\n\nMinami\n\nT\n\n,\n\nKono\n\nM\n\n,\n\nChishina\n\nH\n\n,\n\nTakita\n\nM\n\n, et al\n\nEffectiveness of Sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma\n\n.\n\nLiver Cancer\n\n.\n\n2015\n\n;\n\n4\n\n(\n\n4\n\n):\n\n253\n\n–\n\n62\n\n. .\n\n145.\n\nPeck-Radosavljevic\n\nM\n\n,\n\nKudo\n\nM\n\n,\n\nRaoul\n\nJ-L\n\n,\n\nLee\n\nHC\n\n,\n\nDecaens\n\nT\n\n,\n\nHeo\n\nJ\n\n, et al\n\nOutcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis\n\n.\n\nJ Clin Oncol\n\n.\n\n2018\n\n;\n\n36\n\n(\n\n15 Suppl\n\n):\n\n4018\n\n(suppl; abstr 4018). .\n\n146.\n\nIkeda\n\nM\n\n,\n\nMitsunaga\n\nS\n\n,\n\nShimizu\n\nS\n\n,\n\nOhno\n\nI\n\n,\n\nTakahashi\n\nH\n\n,\n\nOkuyama\n\nH\n\n, et al\n\nEfficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization\n\n.\n\nJ Gastroenterol\n\n.\n\n2014\n\n;\n\n49\n\n(\n\n5\n\n):\n\n932\n\n–\n\n40\n\n. .\n\n147.\n\nKodama\n\nK\n\n,\n\nKawaoka\n\nT\n\n,\n\nAikata\n\nH\n\n,\n\nUchikawa\n\nS\n\n,\n\nInagaki\n\nY\n\n,\n\nHatooka\n\nM\n\n, et al\n\nComparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status\n\n.\n\nJ Gastroenterol Hepatol\n\n.\n\n2018\n\n;\n\n33\n\n(\n\n10\n\n):\n\n1780\n\n–\n\n6\n\n. .\n\n148.\n\nKudo\n\nM\n\n.\n\nA new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE\n\n.\n\nLiver Cancer\n\n.\n\n2019\n\n;\n\n8\n\n(\n\n5\n\n):\n\n299\n\n–\n\n311\n\n. .\n\n149.\n\nKudo\n\nM\n\n,\n\nUeshima\n\nK\n\n,\n\nChan\n\nS\n\n,\n\nMinami\n\nT\n\n,\n\nChishina\n\nH\n\n,\n\nAoki\n\nT\n\n, et al\n\nLenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: a proof-of-concept study\n\n.\n\nCancers\n\n.\n\n2019 Jul 31\n\n;\n\n11\n\n(\n\n8\n\n):\n\n1084\n\n.\n\n150.\n\nKudo\n\nM\n\n,\n\nHan\n\nKH\n\n,\n\nYe\n\nSL\n\n,\n\nZhou\n\nJ\n\n,\n\nHuang\n\nYH\n\n,\n\nLin\n\nSM\n\n, et al\n\nA changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements\n\n.\n\nLiver Cancer\n\n.\n\n2020\n\n;\n\n9\n\n(\n\n3\n\n):\n\n245\n\n–\n\n60\n\n. .\n\n151.\n\nKudo\n\nM\n\n.\n\nHeterogeneity and subclassification of Barcelona clinic liver cancer stage B\n\n.\n\nLiver Cancer\n\n.\n\n2016\n\n;\n\n5\n\n(\n\n2\n\n):\n\n91\n\n–\n\n6\n\n. .\n\n152.\n\nLlovet\n\nJM\n\n,\n\nReal\n\nMI\n\n,\n\nMontaña\n\nX\n\n,\n\nPlanas\n\nR\n\n,\n\nColl\n\nS\n\n,\n\nAponte\n\nJ\n\n, et al\n\nArterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial\n\n.\n\nLancet\n\n.\n\n2002\n\n;\n\n359\n\n(\n\n9319\n\n):\n\n1734\n\n–\n\n9\n\n. .\n\n153.\n\nLlovet\n\nJM\n\n,\n\nVilana\n\nR\n\n,\n\nBrú\n\nC\n\n,\n\nBianchi\n\nL\n\n,\n\nSalmeron\n\nJM\n\n,\n\nBoix\n\nL\n\n, et al\n\nIncreased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma\n\n.\n\nHepatology\n\n.\n\n2001\n\n;\n\n33\n\n(\n\n5\n\n):\n\n1124\n\n–\n\n9\n\n. .\n\n154.\n\nBruix\n\nJ\n\n,\n\nReig\n\nM\n\n,\n\nSherman\n\nM\n\n.\n\nEvidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma\n\n.\n\nGastroenterology\n\n.\n\n2016\n\n;\n\n150\n\n(\n\n4\n\n):\n\n835\n\n–\n\n53\n\n. .\n\n155.\n\nKudo\n\nM\n\n.\n\nExtremely high objective response rate of lenvatinib: its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma\n\n.\n\nLiver Cancer\n\n.\n\n2018\n\n;\n\n7\n\n(\n\n3\n\n):\n\n215\n\n–\n\n24\n\n. .\n\n156.\n\nKudo\n\nM\n\n,\n\nArizumi\n\nT\n\n,\n\nUeshima\n\nK\n\n,\n\nSakurai\n\nT\n\n,\n\nKitano\n\nM\n\n,\n\nNishida\n\nN\n\n.\n\nSubclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi’s subclassification (Kinki criteria)\n\n.\n\nDig Dis\n\n.\n\n2015\n\n;\n\n33\n\n(\n\n6\n\n):\n\n751\n\n–\n\n8\n\n. .\n\n157.\n\nMazzaferro\n\nV\n\n,\n\nLlovet\n\nJM\n\n,\n\nMiceli\n\nR\n\n,\n\nBhoori\n\nS\n\n,\n\nSchiavo\n\nM\n\n,\n\nMariani\n\nL\n\n, et al\n\nPredicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis\n\n.\n\nLancet Oncol\n\n.\n\n2009\n\n;\n\n10\n\n(\n\n1\n\n):\n\n35\n\n–\n\n43\n\n. .\n\n158.\n\nArizumi\n\nT\n\n,\n\nMinami\n\nT\n\n,\n\nChishina\n\nH\n\n,\n\nKono\n\nM\n\n,\n\nTakita\n\nM\n\n,\n\nYada\n\nN\n\n, et al\n\nTime to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in Kinki criteria stages B1 and B2\n\n.\n\nDig Dis\n\n.\n\n2017\n\n;\n\n35\n\n(\n\n6\n\n):\n\n589\n\n–\n\n97\n\n. .\n\n159.\n\nYasui\n\nY\n\n,\n\nTsuchiya\n\nK\n\n,\n\nKurosaki\n\nM\n\n,\n\nTakeguchi\n\nT\n\n,\n\nTakeguchi\n\nY\n\n,\n\nOkada\n\nM\n\n, et al\n\nUp-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization\n\n.\n\nHepatol Res\n\n.\n\n2018\n\n;\n\n48\n\n(\n\n6\n\n):\n\n442\n\n–\n\n50\n\n. .\n\n160.\n\nKimura\n\nH\n\n,\n\nOhkawa\n\nK\n\n,\n\nMiyazaki\n\nM\n\n,\n\nSakakibara\n\nM\n\n,\n\nImanaka\n\nK\n\n,\n\nTamura\n\nT\n\n, et al\n\nSubclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers\n\n.\n\nHepatol Int\n\n.\n\n2017\n\n;\n\n11\n\n(\n\n1\n\n):\n\n105\n\n–\n\n14\n\n. .\n\n161.\n\nEso\n\nY\n\n,\n\nTakai\n\nA\n\n,\n\nTakahashi\n\nK\n\n,\n\nUeda\n\nY\n\n,\n\nTaura\n\nK\n\n,\n\nMarusawa\n\nH\n\n, et al\n\nCombination of Mac-2 binding protein glycosylation isomer and up-to-seven criteria as a useful predictor for Child-Pugh grade deterioration after transarterial chemoembolization for hepatocellular carcinoma\n\n.\n\nCancers\n\n.\n\n2019\n\n;\n\n11\n\n(\n\n3\n\n):\n\n405\n\n. .\n\n162.\n\nIzumoto\n\nH\n\n,\n\nHiraoka\n\nA\n\n,\n\nIshimaru\n\nY\n\n,\n\nMurakami\n\nT\n\n,\n\nKitahata\n\nS\n\n,\n\nUeki\n\nH\n\n, et al\n\nValidation of newly proposed time to transarterial chemoembolization progression in intermediate-stage hepatocellular carcinoma cases\n\n.\n\nOncology\n\n.\n\n2017\n\n;\n\n93\n\n(\n\nSuppl 1\n\n):\n\n120\n\n–\n\n6\n\n. .\n\n163.\n\nHiraoka\n\nA\n\n,\n\nKumada\n\nT\n\n,\n\nKudo\n\nM\n\n,\n\nHirooka\n\nM\n\n,\n\nKoizumi\n\nY\n\n,\n\nHiasa\n\nY\n\n, et al\n\nHepatic function during repeated TACE procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis\n\n.\n\nDig Dis\n\n.\n\n2017\n\n;\n\n35\n\n(\n\n6\n\n):\n\n602\n\n–\n\n10\n\n. .\n\n164.\n\nKanai\n\nT\n\n,\n\nHirohashi\n\nS\n\n,\n\nUpton\n\nMP\n\n,\n\nNoguchi\n\nM\n\n,\n\nKishi\n\nK\n\n,\n\nMakuuchi\n\nM\n\n, et al\n\nPathology of small hepatocellular carcinoma. A proposal for a new gross classification\n\n.\n\nCancer\n\n.\n\n1987\n\n;\n\n60\n\n(\n\n4\n\n):\n\n810\n\n–\n\n9\n\n. .\n\n165.\n\nYamashita\n\nY\n\n,\n\nMatsukawa\n\nT\n\n,\n\nArakawa\n\nA\n\n,\n\nHatanaka\n\nY\n\n,\n\nUrata\n\nJ\n\n,\n\nTakahashi\n\nM\n\n.\n\nUS-guided liver biopsy: predicting the effect of interventional treatment of hepatocellular carcinoma\n\n.\n\nRadiology\n\n.\n\n1995\n\n;\n\n196\n\n(\n\n3\n\n):\n\n799\n\n–\n\n804\n\n. .\n\n166.\n\nCarmeliet\n\nP\n\n,\n\nJain\n\nRK\n\n.\n\nAngiogenesis in cancer and other diseases\n\n.\n\nNature\n\n.\n\n2000\n\n;\n\n407\n\n(\n\n6801\n\n):\n\n249\n\n–\n\n57\n\n. .\n\n167.\n\nTohyama\n\nO\n\n,\n\nMatsui\n\nJ\n\n,\n\nKodama\n\nK\n\n,\n\nHata-Sugi\n\nN\n\n,\n\nKimura\n\nT\n\n,\n\nOkamoto\n\nK\n\n, et al\n\nAntitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models\n\n.\n\nJ Thyroid Res\n\n.\n\n2014\n\n;\n\n2014\n\n:\n\n638747\n\n. .\n\n168.\n\nKawamura\n\nY\n\n,\n\nKobayashi\n\nM\n\n,\n\nShindoh\n\nJ\n\n,\n\nKobayashi\n\nY\n\n,\n\nKasuya\n\nK\n\n,\n\nSano\n\nT\n\n, et al\n\n(18)F-Fluorodeoxyglucose uptake in hepatocellular carcinoma as a useful predictor of an extremely rapid response to lenvatinib\n\n.\n\nLiver Cancer\n\n.\n\n2020\n\n;\n\n9\n\n:\n\n84\n\n–\n\n92\n\n.\n\n169.\n\nKawamura\n\nY\n\n,\n\nKobayashi\n\nM\n\n,\n\nShindo\n\nJ\n\n,\n\nKobayashi\n\nY\n\n,\n\nKasuya\n\nK\n\n,\n\nSano\n\nT\n\n, et al\n\nPretreatment heterogeneous enhancement pattern of hepatocellular carcinoma may be a useful new predictor of early response to lenvatinib and overall prognosis\n\n.\n\nLiver Cancer\n\n.\n\n2020 Jun\n\n;\n\n9\n\n:\n\n275\n\n–\n\n92\n\n. Epub ahead of print.\n\n170.\n\nKudo\n\nM\n\n,\n\nUeshima\n\nK\n\n,\n\nAikata\n\nH\n\n,\n\nTamai\n\nT\n\n,\n\nSaito\n\nK\n\n,\n\nIkeda\n\nK\n\n.\n\nAssociation between tumor response by mRECIST and overall survival in patients with poorly differentiated HCC in REFLECT study. 10th Asia-Pacific Primary Liver Cancer Expert\n\n. .\n\n171.\n\nUeshima\n\nK\n\n,\n\nKudo\n\nM\n\n,\n\nTanaka\n\nM\n\n,\n\nKumada\n\nT\n\n,\n\nChung\n\nH\n\n,\n\nHagiwara\n\nS\n\n, et al\n\nPhase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil\n\n.\n\nLiver Cancer\n\n.\n\n2015\n\n;\n\n4\n\n(\n\n4\n\n):\n\n263\n\n–\n\n73\n\n. .\n\n172.\n\nIkeda\n\nM\n\n,\n\nShimizu\n\nS\n\n,\n\nSato\n\nT\n\n,\n\nMorimoto\n\nM\n\n,\n\nKojima\n\nY\n\n,\n\nInaba\n\nY\n\n, et al\n\nSorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial\n\n.\n\nAnn Oncol\n\n.\n\n2016\n\n;\n\n27\n\n(\n\n11\n\n):\n\n2090\n\n–\n\n6\n\n. .\n\n173.\n\nKudo\n\nM\n\n,\n\nUeshima\n\nK\n\n,\n\nYokosuka\n\nO\n\n,\n\nOgasawara\n\nS\n\n,\n\nObi\n\nS\n\n,\n\nIzumi\n\nN\n\n, et al\n\nSorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial\n\n.\n\nLancet Gastroenterol Hepatol\n\n.\n\n2018\n\n;\n\n3\n\n(\n\n6\n\n):\n\n424\n\n–\n\n32\n\n. .\n\n174.\n\nHe\n\nM\n\n,\n\nLi\n\nQ\n\n,\n\nZou\n\nR\n\n,\n\nShen\n\nJ\n\n,\n\nFang\n\nW\n\n,\n\nTan\n\nG\n\n, et al\n\nSorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial\n\n.\n\nJAMA Oncol\n\n.\n\n2019\n\n;\n\n5\n\n(\n\n7\n\n):\n\n953\n\n–\n\n60\n\n. .\n\n175.\n\nUeshima\n\nK\n\n,\n\nOgasawara\n\nS\n\n,\n\nIkeda\n\nM\n\n,\n\nYasui\n\nY\n\n,\n\nTerashima\n\nT\n\n,\n\nYamashita\n\nT\n\n, et al\n\nHepatic arterial infusion chemotherapy versus sorafenib in patients with advanced hepatocellular carcinoma\n\n.\n\nLiver Cancer\n\n.\n\n2020 Sep\n\n;\n\n9\n\n(\n\n5\n\n):\n\n583\n\n–\n\n95\n\n.\n\n176.\n\nTerashima\n\nT\n\n,\n\nYamashita\n\nT\n\n,\n\nArai\n\nK\n\n,\n\nSunagozaka\n\nH\n\n,\n\nKitahara\n\nM\n\n,\n\nNakagawa\n\nH\n\n, et al\n\nFeasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib\n\n.\n\nHepatol Res\n\n.\n\n2014\n\n;\n\n44\n\n(\n\n12\n\n):\n\n1179\n\n–\n\n85\n\n. .\n\n177.\n\nLlovet\n\nJM\n\n,\n\nRicci\n\nS\n\n,\n\nMazzaferro\n\nV\n\n,\n\nHilgard\n\nP\n\n,\n\nGane\n\nE\n\n,\n\nBlanc\n\nJF\n\n, et al\n\nSorafenib in advanced hepatocellular carcinoma\n\n.\n\nN Engl J Med\n\n.\n\n2008\n\n;\n\n359\n\n(\n\n4\n\n):\n\n378\n\n–\n\n90\n\n. .\n\n178.\n\nCheng\n\nAL\n\n,\n\nKang\n\nYK\n\n,\n\nChen\n\nZ\n\n,\n\nTsao\n\nCJ\n\n,\n\nQin\n\nS\n\n,\n\nKim\n\nJS\n\n, et al\n\nEfficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial\n\n.\n\nLancet Oncol\n\n.\n\n2009\n\n;\n\n10\n\n(\n\n1\n\n):\n\n25\n\n–\n\n34\n\n. .\n\n179.\n\nBruix\n\nJ\n\n,\n\nQin\n\nS\n\n,\n\nMerle\n\nP\n\n,\n\nGranito\n\nA\n\n,\n\nHuang\n\nYH\n\n,\n\nBodoky\n\nG\n\n, et al\n\nRegorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial\n\n.\n\nLancet\n\n.\n\n2017\n\n;\n\n389\n\n(\n\n10064\n\n):\n\n56\n\n–\n\n66\n\n. .\n\n180.\n\nZhu\n\nAX\n\n,\n\nKang\n\nYK\n\n,\n\nYen\n\nCJ\n\n,\n\nFinn\n\nRS\n\n,\n\nGalle\n\nPR\n\n,\n\nLlovet\n\nJM\n\n, et al\n\nRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial\n\n.\n\nLancet Oncol\n\n.\n\n2019\n\n;\n\n20\n\n:\n\n282\n\n–\n\n96\n\n.\n\n181.\n\nAbou-Alfa\n\nGK\n\n,\n\nMeyer\n\nT\n\n,\n\nCheng\n\nAL\n\n,\n\nEl-Khoueiry\n\nAB\n\n,\n\nRimassa\n\nL\n\n,\n\nRyoo\n\nBY\n\n, et al\n\nCabozantinib in patients with advanced and progressing hepatocellular carcinoma\n\n.\n\nN Engl J Med\n\n.\n\n2018\n\n;\n\n379\n\n(\n\n1\n\n):\n\n54\n\n–\n\n63\n\n. .\n\n182.\n\nKudo\n\nM\n\n,\n\nTsuchiya\n\nK\n\n,\n\nKato\n\nN\n\n,\n\nHagihara\n\nA\n\n,\n\nNumata\n\nK\n\n,\n\nAikata\n\nH\n\n, et al\n\nCabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study\n\n.\n\nJ Gastroenterol\n\n.\n\n2021\n\n;\n\n56\n\n(\n\n2\n\n):\n\n181\n\n–\n\n90\n\n.\n\n183.\n\nEl-Khoueiry\n\nAB\n\n,\n\nSangro\n\nB\n\n,\n\nYau\n\nT\n\n,\n\nCrocenzi\n\nTS\n\n,\n\nKudo\n\nM\n\n,\n\nHsu\n\nC\n\n, et al\n\nNivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial\n\n.\n\nLancet\n\n.\n\n2017\n\n;\n\n389\n\n(\n\n10088\n\n):\n\n2492\n\n–\n\n502\n\n. .\n\n184.\n\nZhu\n\nAX\n\n,\n\nFinn\n\nRS\n\n,\n\nEdeline\n\nJ\n\n,\n\nCattan\n\nS\n\n,\n\nOgasawara\n\nS\n\n,\n\nPalmer\n\nD\n\n, et al\n\nPembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial\n\n.\n\nLancet Oncol\n\n.\n\n2018\n\n;\n\n19\n\n(\n\n7\n\n):\n\n940\n\n–\n\n52\n\n. .\n\n185.\n\nFinn\n\nRS\n\n,\n\nRyoo\n\nB-Y\n\n,\n\nMerle\n\nP\n\n,\n\nKudo\n\nM\n\n,\n\nBouattour\n\nM\n\n,\n\nLim\n\nHY\n\n, et al\n\nPembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial\n\n.\n\nJ Clin Oncol\n\n.\n\n2020\n\n;\n\n38\n\n(\n\n3\n\n):\n\n193\n\n–\n\n202\n\n. .\n\n186.\n\nYau\n\nT\n\n,\n\nPark\n\nJW\n\n,\n\nFinn\n\nRS\n\n,\n\nCheng\n\nAL\n\n,\n\nMathurin\n\nP\n\n,\n\nEdeline\n\nJ\n\n, et al\n\nCheckMate 459: a randomized, multi-center phase III study of nivolumab vs sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma\n\n.\n\nAnn Oncol\n\n.\n\n2019\n\n;\n\n30\n\n(\n\nSuppl 5\n\n):\n\nv874\n\n–\n\n5\n\n.\n\n187.\n\nFinn\n\nRS\n\n,\n\nQin\n\nS\n\n,\n\nIkeda\n\nM\n\n,\n\nGalle\n\nPR\n\n,\n\nDucreux\n\nM\n\n,\n\nKim\n\nT-Y\n\n, et al\n\nAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma\n\n.\n\nN Engl J Med\n\n.\n\n2020\n\n;\n\n382\n\n(\n\n20\n\n):\n\n1894\n\n–\n\n905\n\n. .\n\n188.\n\nKudo\n\nM\n\n.\n\nA paradigm change in the treatment strategy for hepatocellular carcinoma\n\n.\n\nLiver Cancer\n\n.\n\n2020\n\n;\n\n9\n\n(\n\n4\n\n):\n\n367\n\n–\n\n77\n\n. .\n\n189.\n\nKudo\n\nM\n\n.\n\nA new era in systemic therapy for hepatocellular carcinoma: atezolizumab plus bevacizumab combination therapy\n\n.\n\nLiver Cancer\n\n.\n\n2020\n\n;\n\n9\n\n(\n\n2\n\n):\n\n119\n\n–\n\n37\n\n. .\n\n190.\n\nFinn\n\nRS\n\n,\n\nIkeda\n\nM\n\n,\n\nZhu\n\nAX\n\n,\n\nSung\n\nMW\n\n,\n\nBaron\n\nAD\n\n,\n\nKudo\n\nM\n\n, et al\n\nPhase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma\n\n.\n\nJ Clin Oncol\n\n.\n\n2020 Sep 10\n\n;\n\n38\n\n(\n\n26\n\n):\n\n2960\n\n–\n\n70\n\n.\n\n191.\n\nKelley\n\nRK\n\n,\n\nKudo\n\nM\n\n,\n\nHarris\n\nW\n\n,\n\nIkeda\n\nM\n\n,\n\nOkusaka\n\nT\n\n,\n\nKang\n\nYK\n\n, et al\n\nThe novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma\n\n.\n\nILCA\n\n.\n\n2020\n\n. (Virtual Conference).\n\n192.\n\nYau\n\nT\n\n,\n\nKang\n\nYK\n\n,\n\nKim\n\nTY\n\n,\n\nEl-Khoueiry\n\nAB\n\n,\n\nSantoro\n\nA\n\n,\n\nSangro\n\nB\n\n, et al\n\nNivolumab plus ipilimumab in advanced hepatocellular carcinoma previously treated with sorafenib (CheckMate 040): a randomized clinical trial\n\n.\n\nJAMA Oncol\n\n.\n\n2020 Oct 1\n\n;\n\n6\n\n(\n\n11\n\n):\n\ne204564\n\n.\n\n193.\n\nKudo\n\nM\n\n.\n\nImmuno-oncology therapy for hepatocellular carcinoma: current status and ongoing trials\n\n.\n\nLiver Cancer\n\n.\n\n2019\n\n;\n\n8\n\n(\n\n4\n\n):\n\n221\n\n–\n\n38\n\n. .\n\n194.\n\nHiraoka\n\nA\n\n,\n\nKumada\n\nT\n\n,\n\nKariyama\n\nK\n\n,\n\nTakaguchi\n\nK\n\n,\n\nAtsukawa\n\nM\n\n,\n\nItobayashi\n\nE\n\n, et al\n\nClinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis\n\n.\n\nCancer Med\n\n.\n\n2019\n\n;\n\n8\n\n(\n\n1\n\n):\n\n137\n\n–\n\n46\n\n. .\n\n195.\n\nThe Japanese Liver Transplantation Society\n\n.\n\nLiver transplantation in Japan-Registry by the Japanese Liver Transplantation Society\n\n.\n\n2019\n\n;\n\n54\n\n:\n\n81\n\n–\n\n96\n\n.\n\n196.\n\nNouso\n\nK\n\n,\n\nMiyahara\n\nK\n\n,\n\nUchida\n\nD\n\n,\n\nKuwaki\n\nK\n\n,\n\nIzumi\n\nN\n\n,\n\nOmata\n\nM\n\n, et al\n\nEffect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan\n\n.\n\nBr J Cancer\n\n.\n\n2013\n\n;\n\n109\n\n(\n\n7\n\n):\n\n1904\n\n–\n\n7\n\n. .\n\n197.\n\nBruix\n\nJ\n\n,\n\nRaoul\n\nJL\n\n,\n\nSherman\n\nM\n\n,\n\nMazzaferro\n\nV\n\n,\n\nBolondi\n\nL\n\n,\n\nCraxi\n\nA\n\n, et al\n\nEfficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial\n\n.\n\nJ Hepatol\n\n.\n\n2012\n\n;\n\n57\n\n(\n\n4\n\n):\n\n821\n\n–\n\n9\n\n. .\n\n198.\n\nKokudo\n\nT\n\n,\n\nHasegawa\n\nK\n\n,\n\nMatsuyama\n\nY\n\n,\n\nTakayama\n\nT\n\n,\n\nIzumi\n\nN\n\n,\n\nKadoya\n\nM\n\n, et al\n\nSurvival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion\n\n.\n\nJ Hepatol\n\n.\n\n2016\n\n;\n\n65\n\n(\n\n5\n\n):\n\n938\n\n–\n\n43\n\n. .\n\n199.\n\nKokudo\n\nT\n\n,\n\nHasegawa\n\nK\n\n,\n\nMatsuyama\n\nY\n\n,\n\nTakayama\n\nT\n\n,\n\nIzumi\n\nN\n\n,\n\nKadoya\n\nM\n\n, et al\n\nLiver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey\n\n.\n\nHepatology\n\n.\n\n2017\n\n;\n\n66\n\n(\n\n2\n\n):\n\n510\n\n–\n\n7\n\n. .\n\n200.\n\nKudo\n\nM\n\n.\n\nManagement of hepatocellular carcinoma in Japan as a world-leading model\n\n.\n\nLiver Cancer\n\n.\n\n2018\n\n;\n\n7\n\n:\n\n134\n\n–\n\n47\n\n.\n\n201.\n\nKudo\n\nM\n\n.\n\nJapan’s successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance\n\n.\n\nLiver Cancer\n\n.\n\n2012\n\n;\n\n1\n\n(\n\n3–4\n\n):\n\n141\n\n–\n\n3\n\n. .\n\n202.\n\nKudo\n\nM\n\n,\n\nIzumi\n\nN\n\n,\n\nSakamoto\n\nM\n\n,\n\nMatsuyama\n\nY\n\n,\n\nIchida\n\nT\n\n,\n\nNakashima\n\nO\n\n, et al\n\nSurvival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan\n\n.\n\nLiver Cancer\n\n.\n\n2016\n\n;\n\n5\n\n(\n\n3\n\n):\n\n190\n\n–\n\n7\n\n. .\n\n203.\n\nKudo\n\nM\n\n,\n\nLencioni\n\nR\n\n,\n\nMarrero\n\nJA\n\n,\n\nVenook\n\nAP\n\n,\n\nBronowicki\n\nJP\n\n,\n\nChen\n\nXP\n\n, et al\n\nRegional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study\n\n.\n\nLiver Int\n\n.\n\n2016\n\n;\n\n36\n\n(\n\n8\n\n):\n\n1196\n\n–\n\n205\n\n. ."
    }
}